Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ X ]
Based on the closing sale price on March 20, 2002, the aggregate market value of the voting stock held by non-affiliates of the registrant was $922,660,324. For these purposes, the registrant considers all of its Directors and executive officers to be its only affiliates.
The number of shares outstanding of the registrant's Common Stock was 33,943,964 on March 20, 2002.
DOCUMENTS INCORPORATED BY REFERENCE
LOCATION IN FORM 10-K |
INCORPORATED DOCUMENT |
Part III |
Specifically identified portions of the Company's |
definitive proxy statement to be filed in |
|
connection with the Company's Annual Meeting to be |
|
held on May 15, 2002 are incorporated herein by |
|
reference. |
Page 1
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Annual Report on Form 10-K, including statements relating to management's expectations regarding new product introductions; the adequacy of the Company's sources for certain components, raw materials and finished products; and the Company's ability to utilize certain inventory. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause IDEXX's results to differ materially from those indicated by such forward-looking statements, including those detailed under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies" and "- Future Operating Results."
In addition, any forward-looking statements represent the Company's estimates only as of the day this Annual Report was first filed with the Securities and Exchange Commission and should not be relied upon as representing the Company's estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if its estimates change.
PART I.
ITEM 1. BUSINESS
IDEXX Laboratories, Inc. ("we", "us", the "Company" or "IDEXX", which includes wholly-owned subsidiaries unless the context otherwise requires), develops, manufactures and distributes products and provides services for veterinary, food and environmental markets. Our products and services include:
· point of care veterinary diagnostic products;
· laboratory and consulting services used by veterinarians;
· veterinary pharmaceutical products;
· information products and services, including software, used in animal health applications;
· diagnostic and health monitoring products and services for production animals;
· products that test water for certain microbiological contaminants; and
· products that test milk for antibiotic residues.
Most of our sales are derived from the sale of our veterinary diagnostic products and services.
We are a Delaware corporation and were incorporated in 1983. Our principal executive offices are located at One IDEXX Drive, Westbrook, Maine 04092, and our telephone number is (207) 856-0300.
|
IDEXX â , ACAREXX ä , Better Choice ä , Colilert â , Colisure
â , Defined Substrate Technology â , DST â , Enterolert ä , LacTek Ô ,LaserCyte ä , Parallux â , PetChek â , Quanti-Tray â , SNAP â , VetConnect â , VetLyte â , VetTest â and 3Dx ä are trademarks of the Company. Cornerstone â is used under a license agreement. Autoread ä , QBC â and VetAutoread ä are trademarks of Becton Dickinson and Company ("Becton Dickinson"). All other products and company names are trademarks of their respective holders.Page 2
PRODUCTS AND SERVICES
We operate in two primary business areas: products and services for the veterinary market, which we refer to as our Companion Animal Group ("CAG") segment, and products and services for food and environmental markets, which we refer to as our Food and Environmental Division ("FED") segment. See Note 11 to the financial statements for financial information about our business segments.
* COMPANION ANIMAL GROUP
Immunoassays
We provide a broad range of single-use, hand-held test kits that allow quick (in most cases, less than ten minutes), accurate and convenient testing for a variety of companion animal diseases and health conditions. These products enable veterinarians to provide improved service to animal owners by delivering test results in the clinic, allowing the veterinarian to initiate therapy or prevention during the office visit, if required.
Our test kits incorporate immunoassay technology based on antibody-antigen reactions. Antibodies are proteins produced as a result of an immune response, a biological mechanism that enables certain animals to recognize and respond to substances foreign to the body, called antigens. Antibodies are produced by the immune system specifically to bind to these antigens and also to signal other immune system cells to assist in eliminating the antigen. Antigens include viruses, bacteria, parasites and hormones. In immunoassay-based tests, a sample containing an unknown quantity of the analyte is mixed with one or more reagents. Certain of these reagents contain either antibodies or antigens that bind in a highly specific manner to the analyte. Certain reagents are labeled with an indicator chemical, which identifies the presence or absence of the analyte. In some cases results can be read visually; in others, instruments are used to determine the results.
Our principal single-use tests are sold under the SNAP name, and include tests for feline leukemia virus ("FeLV") in cats and heartworm disease in dogs and cats. We also sell a feline combination test, the SNAP Combo FeLV/FIV, which enables veterinarians to test simultaneously for FeLV and feline immunodeficiency virus ("FIV") (similar to the human AIDS virus), and a canine combination test, the SNAP 3Dx, which tests simultaneously for Lyme disease, Ehrlichia canis and heartworm. Sales of heartworm tests are significantly greater in the first half of our fiscal year due to seasonality of the disease.
In addition to our single-use tests, we sell a line of microwell-based test kits, under the PetChek name, which are used by larger clinics and independent laboratories to test multiple samples. PetChek tests offer accuracy, ease of use and cost advantages to high-volume customers. We currently sell PetChek tests for FeLV, FIV and canine heartworm disease.
Instruments
We currently market several instrument systems for use in veterinary clinics. These instruments include the following:
Blood Chemistry . Our VetTest blood chemistry analyzer is used to measure levels of certain enzymes and other substances in blood in order to assist the veterinarian in diagnosing physiologic conditions. Twenty-one separate blood chemistry tests can be performed on the VetTest analyzer. Commonly run tests include glucose, alkaline phosphatase, ALT (alanine aminotransferase), creatinine, BUN (blood urea nitrogen) and total protein.
Hematology . The QBC â VetAutoread ä hematology analyzer is used to evaluate certain components of blood, including red blood cells, white blood cells and platelets. These values are useful in determining disease state and health conditions. This system is based on the Becton Dickinson QBC â Autoread ä hematology system, which is sold to physicians for human applications. We also are developing a new hematology system called the LaserCyte system, which uses laser flow cytometry technology. The LaserCyte system is designed to provide certain diagnostic capabilities that cannot be obtained from existing in-clinic systems, which will provide veterinarians with more information necessary to make important clinical decisions regarding an animal's health. We expect to introduce the LaserCyte system in the second half of 2002.
Quantitative Hormone Testing . The VetTest SNAP Reader allows the veterinarian to obtain quantitative measurement of hormones including thyroxine and cortisol. These measurements assist in diagnosing and monitoring the treatment of certain endocrine diseases, such as hyper- and hypo-thyroidism, Cushing's syndrome and Addison's disease. The VetTest SNAP Reader is a module that can be integrated with the VetTest chemistry analyzer. Samples and reagents are introduced to the analyzer using our SNAP device.
Page 3
Electrolytes . Our VetLyte system measures three electrolytes -- sodium, potassium and chloride -- to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Test results are available in less than one minute after sample introduction and are either displayed on the VetLyte analyzer or downloaded to the VetTest analyzer.
Veterinary Laboratory and Consulting Services
We offer commercial veterinary laboratory and consulting services in the U.S. through facilities located in Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, Oregon and Texas. Through subsidiaries located in the United Kingdom, Japan and Australia, we offer commercial veterinary laboratory services to veterinary clinics located in those countries. Veterinarians use our services by submitting samples by courier or overnight delivery to one of our facilities. Our laboratories offer a large selection of tests and diagnostic panels to detect a number of disease states and other conditions in production and companion animals.
Additionally, we provide specialized veterinary consultation, telemedicine and advisory services, including cardiology, radiology, internal medicine, dermatology and ultrasound consulting. These services permit veterinarians to obtain readings and interpretations of test results transmitted by telephone and over the Internet from the veterinarians' offices.
Approximately 74%, 75% and 69% of our revenues were derived from sales of veterinary diagnostic products and services within the CAG segment in 2001, 2000 and 1999, respectively.
Information Products and Services
Our practice management information software business was formed in 1997 with the acquisitions of Advanced Veterinary Systems and Professionals' Software, Inc. Veterinarians use practice information management software to run key functions of their clinics, including scheduling, billing and patient records management. In January 2000, we launched vetconnect.com, an Internet portal for the veterinary medical market. Vetconnect.com is a comprehensive suite of information and business services designed to support veterinary medical practice and extend the value of our in-clinic products, laboratory and consulting services and information offerings. We believe we are the leading provider of veterinary practice information management software systems in the U.S. with an installed based of more than 8,000 of the approximately 25,000 veterinary hospitals in North America. We also provide software and hardware support and derive a significant portion of our revenues for this product line from ongoing service contracts.
Veterinary Pharmaceuticals
In October 1998, we acquired Blue Ridge Pharmaceuticals, Inc. ("Blue Ridge"), a privately-held company engaged in the development of novel therapeutics for the veterinary market. Blue Ridge was formed in 1996 to develop products for therapeutic applications in companion animals and livestock that might not fit the strategic goals of larger pharmaceutical companies marketing both human and veterinary products. In December 2000, we introduced ACAREXX (.01% Ivermectin) otic suspension for the treatment of ear mites in cats. ACAREXX is our first drug approved by the U.S. Food and Drug Administration ("FDA"). We currently have a number of other products in the registration process with the FDA, including a nitazoxanide-based product for treatment of equine protozoal myeloencephalitis, a neurological disease that is believed to affect approximately 200,000 horses in the U.S.; a topical non-steroidal anti-inflammatory for equine use; an insulin product for treatment of diabetic cats; and a long-acting, injectable antibiotic for cats.
* FOOD AND ENVIRONMENTAL DIVISION
We sell products that detect microbial contaminants in water and antibiotic residues in milk, and a broad range of diagnostic and health monitoring products for production animals (primarily poultry, livestock and swine).
Approximately 20%, 20% and 22% of our revenues were derived from sales of food and environmental products and services in 2001, 2000 and 1999, respectively. Through a series of transactions completed late in 1999 and early 2000, we disposed of our food microbiology testing products and services business. Revenues from this disposed product line were approximately $0.8 million and $14.0 million in 2000 and 1999, respectively.
Page 4
Water and Dairy Testing Products
Our Colilert, Colilert-18 and Colisure tests, based on patented Defined Substrate Technology ("DST"), simultaneously detect total coliforms and E. coli in water. These organisms are broadly used as indicators of microbial contamination in water. Our DST products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Our water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water in compliance with U.S. Environmental Protection Agency ("EPA") standards. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.
Our Enterolert product is also based on DST and detects enterococci in drinking and recreational waters, with results available in 24 hours. Our Quanti-Tray product, when used in conjunction with our Colilert, Colilert-18, Colisure or Enterolert products, provides users quantitative measurements of microbial contamination, rather then a presence/absence indication. The Colilert, Colilert-18, Colisure and Quanti-Tray products have been approved by the EPA and by regulatory agencies in certain other countries.
In August 2000, we acquired Genera Technologies Limited, a U.K.-based company that develops and sells products for detection of cryptosporidia in water. Cryptosporidia are parasites that can cause potentially fatal gastrointestinal illness if ingested. Testing of water supplies for cryptosporidia is mandated by regulation in the United Kingdom but is not regulated in other countries at this time.
We are a worldwide leader in rapid testing of antibiotic residue in milk. We offer antibiotic residue tests on our SNAP platform, and we also sell the Parallux system, an instrument-based testing system. Dairy producers and processors use our tests for incoming quality assurance of raw milk, and government and food quality managers use them for ongoing surveillance. IDEXX dairy quality tests are designed for convenience in field and laboratory testing applications and are calibrated to detect antibiotic residues at levels specified by regulation.
Production Animal Services
We sell diagnostic tests and related instrumentation and software that are used to detect a wide range of diseases and monitor health status in production animals. Our production animal products are purchased primarily by government laboratories and poultry and swine producers. Significant products include diagnostic tests for porcine reproductive and respiratory syndrome ("PRRS") and pseudorabies virus in pigs; Newcastle disease in poultry; and Johne's disease and brucellosis in cattle.
MARKETING AND DISTRIBUTION
We market, sell and service our products in more than 50 countries through our marketing, sales and technical service groups as well as through independent distributors and other resellers. We maintain sales offices outside the U.S. in Australia, France, Germany, Italy, Japan, Mexico, The Netherlands, Spain, Taiwan and the United Kingdom.
Generally, we will select the appropriate distribution channel for our products based on the type of product, technical service requirements, number and concentration of customers, regulatory requirements and other factors. We market our veterinary diagnostic products to veterinarians both directly and through independent veterinary distributors in the U.S., with most instruments sold directly by IDEXX sales personnel, and test kits and consumables supplied both via the distribution channel and directly. Outside the U.S., we sell our veterinary diagnostic products through independent distributors and other resellers and, in certain countries, through our direct sales force. We market our software products and veterinary laboratory services through our direct sales force. We market our water, dairy, livestock and poultry products primarily through our direct sales force in the U.S. and Canada. Outside the U.S. and Canada, we market these products through selected independent distributors and, in certain countries, through our direct sales force.
In 2001, 2000 and 1999, 28%, 27% and 27%, respectively, of our revenue was attributable to sales of products and services to customers outside the U.S. Risks associated with foreign operations include the need for additional regulatory approvals, possible disruptions in transportation of our products, the differing product needs of foreign customers, difficulties in building and managing foreign operations, fluctuations in the value of foreign currencies, import/export duties and quotas, and unexpected regulatory, economic or political changes in foreign markets. We engage in limited hedging activities to reduce the effect of foreign currency fluctuations on our earnings. See Note 11 to the financial statements for information by geographic region.
Page 5
In 2001 and 2000, no customer accounted for 10% or more of our sales. In 1999, 10% of our sales were to The Butler Company, a distributor of veterinary products.
RESEARCH AND DEVELOPMENT
Our business includes the development and introduction of new products and may involve entry into new business areas. Our research and development activity is focused primarily on development of new animal drugs, new diagnostic instrument platforms and improvements to our diagnostic and testing products. Our research and development expenses were approximately $28.4, $28.3 and $27.3 million in 2001, 2000 and 1999, respectively.
PATENTS AND LICENSES
We actively seek to obtain patent protection in the U.S. and other countries for inventions covering our products and technologies. We also license patents and technologies from third parties. These licenses include an exclusive royalty-bearing license of certain patents relating to diagnostic products for FIV from The Regents of the University of California, and an exclusive royalty-bearing license of certain patents relating to DST utilized in the Colilert, Colisure and Enterolert water testing products. Licensed U.S. patents related to FIV diagnostics expire in 2008 and 2009. Licensed U.S. patents relating to DST expire in 2007. In addition, we hold a royalty-bearing patent license relating to canine heartworm tests from Barnes-Jewish Hospital. The U.S. patent rights licensed from Barnes-Jewish Hospital expire in 2006.
To the extent some of our products may now, or in the future, embody technologies protected by patents, copyrights or trade secrets of others, we may be required to obtain licenses to such technologies in order to continue to sell our products. These licenses may not be available on commercially reasonable terms. Our failure to obtain any such licenses may delay or prevent the sale of certain new or existing products. See "Management's Discussion and Analysis of Financial Condition and Results of Operations - Future Operating Results."
PRODUCTION AND SUPPLY
VetTest analyzers are manufactured for us by Tokyo Parts Industrial Company Ltd. under an agreement that renews annually unless either party notifies the other of its decision not to renew. The dry chemistry slides used in the VetTest analyzer ("VetTest Slides") are supplied exclusively by Ortho-Clinical Diagnostics, Inc. (formerly known as Johnson and Johnson Clinical Diagnostics, Inc.) ("Ortho") under supply agreements with Ortho (the "Ortho Agreements"). We are required to purchase all of our requirements for slides from Ortho to the extent available. In addition, we have committed to minimum annual purchase volumes of certain VetTest Slides during the term of the Ortho Agreements. The Ortho Agreements do not prohibit Ortho from selling dry chemistry slides for use in veterinary applications, and Ortho currently sells dry chemistry slides for use in its own analyzer, which is primarily designed for human applications but is also used in the veterinary market. However, Ortho may not sell slides that are bar-coded for use in the VetTest analyzer to any party other than IDEXX. The Ortho Agreements expire on December 31, 2010 and contain provisions for the negotiation of a renewal term of five years.
The QBC â VetAutoread ä system is manufactured for us by Becton Dickinson under a development and distribution agreement that requires Becton Dickinson to supply analyzers to us through 2008 and reagents through 2010. Becton Dickinson is the sole source of these analyzers and reagents.
Certain other components of our products also are available from only one source. While we do not anticipate difficulties in obtaining any of the components used in our products, the loss of any of these sources of supply would have a material adverse effect on the Company.
Substantially all of our revenue in each quarter results from orders booked in that quarter. Accordingly, we maintain no significant backlog and believe that our backlog at any particular date is not indicative of future sales.
COMPETITION
We face intense competition within the markets in which we sell our products and services. We expect that future competition will become even more intense, and that we will have to compete with changing technologies, which could affect the marketability of our products and services. Our competitive position also will depend on our ability to develop proprietary products, attract and retain
Page 6
We compete with many companies ranging from small businesses focused on animal health to large pharmaceutical companies. Our competitors vary in our different markets. Academic institutions, governmental agencies and other public and private research organizations also conduct research activities and may commercialize products, which could compete with our products, on their own or through joint ventures. Many of our competitors have substantially greater capital, manufacturing, marketing and research and development resources than us.
Competitive factors in our different business areas are detailed below:
· |
Veterinary diagnostic products and food and environmental test products . We compete primarily on the basis of the ease of |
|
use, speed, accuracy and other performance characteristics of our products and services, the breadth of our product line and |
services, the effectiveness of our sales and distribution channels, the quality of our technical and customer service and |
|
|
pricing. |
· |
Veterinary laboratory services . In this market, we compete primarily on the basis of service, price and quality. We |
compete in certain geographic locations with Antech Diagnostics, a unit of Veterinary Centers of America, Inc. |
|
· |
Veterinary pharmaceuticals . We compete primarily on the basis of the performance characteristics of our products. |
· |
Veterinary practice information management software systems . We compete primarily on the basis of ease of use, speed |
and other performance characteristics, the effectiveness of our customer service, advances in technologies and pricing. |
GOVERNMENT REGULATION
Many of our products are subject to regulation by U.S. and foreign regulatory agencies. The following is a description of the principal regulations affecting our businesses.
Veterinary diagnostic products . Most diagnostic tests for animal health applications are veterinary biological products that are regulated in the U.S. by the Center for Veterinary Biologics within the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS"). The APHIS regulatory approval process involves the submission of product performance data and manufacturing documentation. Following regulatory approval to market a product, APHIS requires that each lot of product be submitted for review before release to customers. In addition, APHIS requires special approval to market products where test results are used in part for government-mandated disease management programs. A number of foreign governments accept APHIS approval as part of their separate regulatory approvals. However, compliance with an extensive regulatory process is required in connection with marketing diagnostic products in Japan, Germany, The Netherlands and many other countries. We also are required to have a facility license from APHIS to manufacture USDA-licensed products. We have obtained such a license for our manufacturing facility in Westbrook, Maine.
Our instrument systems are medical devices regulated by the U.S. Food and Drug Administration ("FDA") under the Food, Drug and Cosmetics Act (the "FDC Act"). While the sale of these products does not require premarket approval by FDA and does not subject us to the FDA's Good Manufacturing Practices regulations ("GMPs"), these products must not be adulterated or misbranded under the FDC Act.
Veterinary pharmaceuticals . The manufacture and sale of veterinary pharmaceuticals are regulated by the Center for Veterinary Medicine ("CVM") of the FDA. A new animal drug may not be commercially marketed in the U.S. unless it has been approved as safe and effective by CVM. Approval may be requested by filing a New Animal Drug Application ("NADA") with CVM containing substantial evidence as to the safety and effectiveness of the drug. For food animals, the data must also include extensive data to support a withdrawal period or other use restriction to ensure that the proposed drug use will produce animals and animal products that are safe for human consumption. Data regarding manufacturing methods and controls is also required to be submitted with the NADA. Manufacturers of animal drugs must also comply with GMPs. Sales of animal drugs in countries outside the U.S. require compliance with the laws of those countries, which may be extensive.
Page 7
Water testing products . Our water tests are not subject to formal premarket regulatory approval. However, before a test may be used as part of a water quality monitoring program required by the EPA, the test must first be approved by the EPA. The EPA approval process involves submission of extensive product performance data in accordance with an EPA approved protocol, evaluation of the data by the EPA and publication for public comment of any proposed approval in the Federal Register before final approval. Our Colilert, Colilert-18, Colisure and Quanti-Tray products have been approved by the EPA. The sale of water testing products also is subject to extensive and lengthy regulatory processes in many other countries around the world.
Dairy testing products . The sale of dairy testing products in the U.S. is regulated by the FDA in conjunction with the Association of Official Analytical Chemists - Research Institute ("AOAC-RI"). Before a product may be sold, extensive product performance data must be submitted in accordance with a protocol that is approved by the FDA and the AOAC-RI. Following approval of a product by FDA, the product must also be approved by the National Conference on Interstate Milk Shipments ("NCIMS"), an oversight body that includes state, federal and industry representatives. Our SNAP Beta-lactam and Parallux dairy antibiotic residue testing products have been approved by the FDA and NCIMS. While some foreign countries accept AOAC-RI approval as part of their regulatory approval process, many countries have separate regulatory processes.
Any acquisitions of new products and technologies may subject us to additional areas of government regulation. These may involve food, drug and water quality regulations of the FDA, the EPA and the USDA, as well as state, local and foreign governments. See "Management's Discussion and Analysis of Financial Condition and Results of Operations - Future Operating Results."
EMPLOYEES
As of December 31, 2001, IDEXX had approximately 2,170 full-time and part-time employees. We are not a party to any collective bargaining agreement and we believe that relations with our employees are good.
ITEM 2. PROPERTIES
We own approximately 12 acres of undeveloped land in Westbrook, Maine. We lease approximately 290,000 square feet of office and manufacturing space in Westbrook, Maine under a lease expiring in 2008, approximately 75,000 square feet of industrial space in Memphis, Tennessee for use as a distribution facility, under a lease expiring in 2007, and approximately 40,000 square feet of office and manufacturing space in Eau Claire, Wisconsin for our veterinary practice information management software business.
We also lease a total of approximately 100,000 square feet of smaller office, manufacturing and warehouse space in the U.S. and elsewhere in the world. In addition, we own or lease approximately 114,000 square feet of space in the U.S., Australia and the United Kingdom for use as veterinary reference laboratories and office space for our veterinary consulting services. Of this space, 46,000 square feet is owned by us and the remaining amount is leased, under leases having expiration dates up to the year 2012.
ITEM 3. LEGAL PROCEEDINGS
We are not a party to any material legal proceedings.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders during the fourth quarter of the fiscal year covered by this report.
EXECUTIVE OFFICERS OF THE COMPANY
Our executive officers as of March 15, 2002 were as follows:
NAME |
AGE |
TITLE |
Jonathan W. Ayers |
45 |
President, Chief Executive Officer and Chairman of the Board of Directors |
Erwin F. Workman, Jr., Ph.D. |
55 |
Executive Vice President and Chief Scientific Officer |
Louis W. Pollock |
48 |
Senior Vice President |
Conan R. Deady |
40 |
Vice President, General Counsel and Secretary |
S. Sam Fratoni, Ph.D. |
54 |
Vice President |
Robert S. Hulsy |
57 |
Vice President |
Merilee Raines |
46 |
Vice President, Finance and Treasurer |
Quentin Tonelli, Ph.D. |
53 |
Vice President |
Page 8
Mr. Ayers has been Chief Executive Officer and President of IDEXX since January 2002. Before joining IDEXX, from January 2000 to October 2001, Mr. Ayers was President of Carrier Corporation, the largest business unit of United Technologies Corporation, a provider of high technology products and services to the building systems and aerospace industries, and from July 1997 to December 1999, he was President of Carrier Asia Pacific Operations. From March 1995 to June 1997, Mr. Ayers was Vice President, Strategic Planning at United Technologies. Before joining United Technologies, from May 1991 to March 1995, Mr. Ayers was Principal of Corporate Finance and from August 1986 to May 1991, he was Vice President of Mergers and Acquisitions, at Morgan Stanley & Co.
Dr. Workman joined the Company in July 1984, and he has served as Executive Vice President and Chief Scientific Officer since November 1997 and as a Director since 1993. He also served as President and Chief Operating Officer from 1993 to November 1997. Before joining the Company, he was Manager of Research and Development for the Hepatitis and AIDS Business Unit within the diagnostic division of Abbott Laboratories, Inc.
Mr. Pollock became Senior Vice President of the Company in July 2000 and was a Vice President from December 1994. He has been President of the Company's Professional Office Diagnostics Division within the Companion Animal Group since July 1999. Mr. Pollock joined the Company in 1986 and served in positions of increasing responsibility in veterinary products sales management before serving as President of the Company's International Division from December 1994 to March 1996 and as President of the Company's Food and Environmental Division from March 1996 until July 1999. Before joining the Company, Mr. Pollock was employed in various sales and marketing positions with Abbott Laboratories, Inc.
Mr. Deady has been Vice President and General Counsel of the Company since August 1999 and was Deputy General Counsel of the Company from June 1997. Before joining the Company in June 1997, Mr. Deady was Deputy General Counsel of Thermo Electron Corporation, a manufacturer of technology-based instruments. Mr. Deady was previously affiliated with Hale and Dorr, a Boston-based law firm.
Dr. Fratoni has been Vice President of the Company since May 1997 and Chief Information Officer since November 2000. He was President of the Company's Food and Environmental Division from July 1999 to December 2000. From May 1997 to July 1999, Dr. Fratoni was Vice President of Human Resources of the Company, and from October 1996 to May 1997, he was Director of Business Development for the Food and Environmental Division. Before joining the Company in October 1996, Dr. Fratoni held various positions with Hewlett Packard Company.
Mr. Hulsy has been Vice President of the Company since February 1999 and President of the Company's IDEXX Veterinary Services subsidiary since August 1998. Before joining the Company in August 1998, Mr. Hulsy was President of American Environmental Network, Inc., a network of environmental laboratories, from 1992 to 1998.
Ms. Raines has been Vice President, Finance of the Company since May 1995. She served as Division Vice President, Finance from March 1995 to May 1995, Director of Finance from 1988 to March 1995 and Controller from 1985 to 1988.
Dr. Tonelli became Vice President of the Company in June 2001. He joined the Company in October 1984 and is currently General Manager of the Production Animal Service Business Unit. Previously he has held various positions with the Company, including Divisional Vice President for Research and Development and Divisional Vice President, Business Development. Before joining the Company, he was a Group Leader of Research and Development for the Hepatitis and AIDS Business Unit within the diagnostic division of Abbott Laboratories, Inc.
Page 9
PART II.
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS
Our Common Stock is quoted on the Nasdaq Stock Market under the symbol IDXX. The table below shows the high and low sale prices per share of our Common Stock as reported on the Nasdaq Stock Market for the years 2000 and 2001.
_HIGH_
__LOW_
CALENDAR 2000
First Quarter
$30.44
$14.50
Second Quarter
29.75
21.13
Third Quarter
28.00
20.50
Fourth Quarter
27.19
20.13
CALENDAR 2001
First Quarter
$25.50
$17.13
Second Quarter
32.38
19.13
Third Quarter
30.90
20.20
Fourth Quarter
30.00
22.38
As of December 31, 2001, there were 1,303 holders of record of our Common Stock.
We have never paid any cash dividends on our Common Stock and do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain future earnings to fund the development and growth of our business.
Page 10
ITEM 6. SELECTED FINANCIAL DATA
The following table sets forth selected consolidated financial data of the Company for each of the five years ended December 31, 2001. The selected consolidated financial data presented below have been derived from the Company's consolidated financial statements, which have been audited by Arthur Andersen LLP, independent public accountants. These financial data should be read in conjunction with the consolidated financial statements, related notes and other financial information appearing elsewhere in this Form 10-K.
_________________________YEARS ENDED DECEMBER 31,_________________________
_____1997_____
_____1998_____
_____1999_____
_____2000_____
_____2001_____
(in thousands, except per share data)
STATEMENT OF OPERATIONS DATA:
Revenue
$ 264,426
$ 321,713
$ 358,370
$ 367,432
$ 386,081
Cost of revenue
144,804
164,240
186,386
190,256
202,750
Gross profit
119,622
157,473
171,984
177,176
183,331
Expenses:
Sales and marketing
63,823
61,725
53,885
54,956
57,087
General and administrative
43,172
43,959
43,969
40,677
41,266
Research and development
17,057
22,687
27,313
28,292
28,426
Non-recurring operating charge
21,300
--
--
--
--
Write-off of in-process research
and development
13,200
37,162
--
--
--
Income (loss) from operations
(38,930)
(8,060)
46,817
53,251
56,552
Interest income, net
6,670
6,877
5,728
4,996
2,229
Net income (loss) before provision for
(benefit of) income taxes
(32,260)
(1,183)
52,545
58,247
58,781
Provision for (benefit of) income taxes
(11,140
)
14,032
19,967
21,615
21,161
Net income (loss)
$ (21,120)
$ (15,215)
$ 32,578
$ 36,632
$ 37,620
Net income (loss) per share:
Basic
$ (0.56)
$ (0.40)
$ 0.85
$ 1.06
$ 1.13
Diluted
(0.56)
(0.40)
0.82
1.02
1.09
Weighted average shares outstanding:
Basic
37,974
38,513
38,412
34,574
33,293
Diluted
37,974
38,513
39,743
36,081
34,640
======
======
======
======
======
___________________________DECEMBER 31,_________________________
___1997____
___1998____
___1999____
___2000____
___2001____
(in thousands)
BALANCE SHEET DATA:
Working capital
$ 205,326
$ 188,829
$ 158,774
$ 141,781
$ 164,199
Total assets
373,064
386,548
357,982
335,796
373,107
Total debt
4,087
9,381
3,543
8,472
8,380
Stockholders' equity
302,733
307,840
284,341
261,747
301,730
Page 11
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF |
OPERATIONS |
We operate primarily through two business segments: the Companion Animal Group ("CAG") and the Food and Environmental Division ("FED"). CAG comprises our veterinary diagnostic products and services, veterinary pharmaceuticals business, and veterinary information products and services. FED comprises our services and products for food and water testing. Through a series of transactions completed in late 1999 and the first quarter of 2000, we sold substantially all of our businesses related to food microbiology testing. FED now comprises our water and dairy testing business and our production animal services business.
* CRITICAL ACCOUNTING POLICIES
The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to customer programs and incentives, product returns, bad debts, inventories, investments, intangible assets, income taxes, warranty obligations, restructuring and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.
Inventory
Our inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out) or market. We write down inventory for estimated obsolescence based upon assumptions about future demand and market conditions, which may negatively affect our ability to dispose of inventory. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which would have a negative effect on our results of operations.
Our inventories as of December 31, 2001 included $8.6 million of raw materials associated with our nitazoxanide product in registration with the FDA, of which $8.4 million will expire and become unusable in 2004 and the remainder has no expiration date. We have completed manufacturing and efficacy components of our submission to the FDA. We have completed additional safety studies requested by the FDA with respect to this product and are preparing a submission reporting the results of these studies. We believe that the product is approvable by the FDA and that this inventory will be saleable upon such approval. If this product is not approved by the FDA, we believe we have the ability to recoup a substantial portion of our costs through alternative future uses of the material or other means. We have provided reserves to cover estimated potential losses in this scenario. However, we cannot provide assurance that the FDA will approve this product or, if approval is not obtained, that our current estimates of recovery of our investment in this inventory will not change.
Our inventories include $30.4 million of slides used in our chemistry instruments, which represents approximately 1.3 turns based on recent historical usage. These slides have a shelf life of 24 months at the date of manufacture. The average remaining shelf life at December 31, 2001 was 16.5 months. In addition, we are required to purchase $289.0 million of slides over the remaining nine years of our contract with Ortho. We believe the demand for these slides is at a level sufficient to ensure that we will not incur a loss on the inventory or the contract. However, a reduction in the demand for slides could cause us to incur a loss related to our slide inventory or purchase commitments at a future date.
Our inventories include $6.0 million of component parts associated with our LaserCyte hematology instrument, which is in the final stages of development. In addition, we have placed $0.9 million in deposits with vendors to secure additional critical components and we have firm purchase commitments of an additional $6.2 million. We expect to launch this product in the second half of 2002 and to fully realize our investment and purchase commitments. However, if we are unable to introduce this product, or if we alter the final design, we may be required to write-off a certain amount of the associated inventory.
The slides, nitazoxanide and LaserCyte products are included in our CAG segment.
Page 12
Valuation of Long-lived and Intangible Assets and Goodwill
We assess the impairment of identifiable intangibles, long-lived assets and goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:
· significant under-performance relative to historical or projected future operating results;
· significant changes in the manner of our use of the acquired assets or the strategy for our overall business; and
· significant negative industry or economic trends.
When we determine that the carrying value of intangibles, long-lived assets and goodwill may not be recoverable based on a change in events and circumstances discussed above, we measure any impairment based on the projected undiscounted cash flow method. Net intangible assets and goodwill amounted to $55.2 million as of December 31, 2001, consisting of $24.3 million related to veterinary laboratories, $15.0 million related to water test products, $14.6 million related to veterinary pharmaceutical products and $1.3 million of other.
In 2002, Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets", became effective and as a result, we will cease to amortize approximately $50.9 million of goodwill. We had recorded approximately $5.1 million of amortization on these amounts during 2001 and would have recorded approximately $4.3 million of amortization during 2002 if the existing standards had been continued. In lieu of amortization, we are required to perform an initial impairment review of our goodwill in 2002 and an annual impairment review thereafter. We expect to complete our initial review during the first half of 2002.
We currently do not expect to record an impairment charge upon completion of the initial impairment review. However, there can be no assurance that at the time the review is completed a material impairment charge will not be recorded.
Revenue Recognition
We recognize product revenue at the time of shipment (including to distributors) for substantially all products except software licenses and hardware systems. We recognize revenue from non-cancelable software licenses and hardware systems upon installation and customer acceptance of the software because at this time collection is probable and we have no significant further obligations after installation. Our distributors do not have the right to return products. Service revenue is recognized at the time the service is performed. Maintenance revenue is billed in advance and recognized over the life of the contracts, usually one year or less. Certain instrument systems are sold to a third-party finance company that leases these systems to its customers with a right-of-return privilege. We allow the third-party finance company to return these instruments to us for a partial refund based on the time from product return to end of lease term. Therefore we recognize revenue under these contracts over the term of the underlying customer lease contract. We lease certain instruments directly to customers and recognize revenues from those leases over the terms of those leases. We record estimated reductions to revenue in connection with customer programs and incentive offerings, which may give customers future rights such as free or discounted goods or services or trade-in rights.
Income Taxes
We account for income taxes under SFAS No. 109, "Accounting for Income Taxes". This statement requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we have considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, an adjustment to the deferred tax asset would increase income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, an adjustment to the deferred tax asset would be charged to income in the period such determination was made.
Page 13
We do not provide for U.S. income taxes on earnings of our subsidiaries outside of the U.S. Our intention is to reinvest these earnings permanently or to repatriate the earnings only when tax-effective to do so. It is not practical to estimate the amount of additional taxes that might be payable upon repatriation of foreign earnings; however, we believe that U.S. foreign tax credits would largely eliminate any U.S. taxes or offset any foreign withholding taxes.
Warranty Reserves
We provide for the estimated cost of product warranties at the time revenue is recognized. Although we engage in extensive product quality programs and processes, our warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Should actual product failure rates or service delivery costs differ from our estimates, which are based on historical data and engineering estimates, where applicable, revisions to the estimated warranty liability would be required.
In the second half of 2002, we expect to introduce the LaserCyte system. We expect that sales of this system will cause warranty expense to increase significantly in 2002. We will charge warranty expense to the cost of LaserCyte sales based upon our experience with instrument sales and engineering information about the system. Should actual warranty expense exceed our estimates, our cost of sales of LaserCyte systems would increase.
* RESULTS OF OPERATIONS
2001 Compared to 2000
COMPANION ANIMAL GROUP
Revenue for CAG increased $12.3 million, or 4% to $308.0 million from $295.7 million in 2000. The increase was attributable primarily to an increase in sales of veterinary reference laboratory services, canine test kits and ACAREXX, a treatment for ear mites in cats, partially offset by unfavorable exchange rates and a decrease in sales of slides. Increased sales of veterinary reference laboratory services were attributable primarily to incremental sales resulting from our acquisition of Veterinary Pathology Services Pty. Ltd. ("VPS") in July 2000 and from increased sales from laboratories in existence during both reporting periods. Decreased sales of slides resulted primarily from a reduction in distributor inventory levels for this product. Increased sales of canine test kits were attributable primarily to increased sales of our Canine SNAP 3Dx combination test, which we introduced in March 2001. Sales of ACAREXX in 2001 were largely incremental to 2000 because we launched this product in December 2000.
As of December 31, 2001 our U.S. veterinary diagnostic product distributors were holding $22.5 million of inventory, or approximately eight weeks based on projected future sales. These distributors were carrying $22.1 million, or approximately nine weeks, of inventory as of December 31, 2000.
Gross profit as a percent of CAG's revenue decreased to 45% from 46% in 2000. Improved margins on veterinary reference laboratory services and the veterinary practice information management software product line were offset by our inability to absorb fixed costs as a result of delays in the launch of our nitazoxanide new animal drug and our LaserCyte hematology instrument and by unfavorable exchange rates. The increased margins from veterinary reference laboratory services were attributable primarily to cost savings from process automation and reduced courier costs. The increase in margin from the veterinary practice information management software product line was attributable primarily to infrastructure reductions in our veterinary Internet portal and customer service operations.
Operating expenses relating to CAG increased $1.1 million, or 1% to $101.2 million from $100.1 million in 2000. The increase was attributable primarily to an increase in veterinary diagnostic sales personnel and related overhead, offset by a decrease in expenses relating to our veterinary practice information management software product line.
FOOD AND ENVIRONMENTAL DIVISION
Revenue for FED increased $6.3 million, or 9% to $78.0 million from $71.7 million in 2000. The increase was attributable primarily to increased sales of water testing products, including incremental revenue from the acquisition of Genera Technologies Limited ("Genera"), partially offset by decreased sales of dairy testing products, the impact of unfavorable exchange rates and decreased sales of food testing products. Sales of dairy testing products declined due to the elimination of our LacTek product in the second quarter of 2001, increased competition and product unavailability due to manufacturing issues. Sales of food testing products declined due to the divestiture of the food microbiology testing business in the first quarter of 2000.
Page 14
Gross profit as a percent of FED's revenue increased to 58% from 57% in 2000. The increase in gross margin percentage was attributable primarily to increased sales of higher margin water testing products, including those products from Genera, partially offset by decreased margins on dairy testing products due to our inability to absorb fixed costs as a result of lower manufacturing volumes.
Operating expenses relating to FED increased $1.1 million, or 5% to $22.8 million from $21.7 million in 2000. The increase was attributable primarily to incremental operating expenses and amortization associated with the acquisition of Genera and a $1.5 million one-time gain on the sale of the food product lines that was recorded as a reduction of operating expenses in 2000, partially offset by the elimination of operating expenses associated with the food product lines.
2000 Compared to 1999
COMPANION ANIMAL GROUP
Revenue for CAG increased $16.3 million, or 6% to $295.7 million from $279.4 million in 1999. The increase was attributable primarily to an increase in sales of veterinary reference laboratory services, VetTest slides and feline and canine test kits. The increase in veterinary reference laboratory services was attributable primarily to incremental revenues from laboratories acquired in 1999 and 2000, including the laboratory businesses of Tufts University School of Veterinary Medicine acquired in December 1999 and VPS acquired in July 2000. The increase in VetTest slides was attributable to an increase in instrument placements, including those through our rental program, and increased customer utilization per instrument. These increases were partially offset by a decrease in sales of veterinary practice information management software systems, which were unusually high in 1999 as a result of customer upgrades made in anticipation of the year 2000.
Gross profit as a percent of CAG's revenue decreased to 46% from 47% in 1999. The reduction in gross margin percentage was attributable primarily to increased sales of lower gross margin veterinary reference laboratory services, higher cost of veterinary instrument service and unabsorbed fixed costs associated with decreased sales of veterinary practice information management software systems, partially offset by increased sales of higher margin instrument consumables.
Operating expenses relating to CAG increased $5.7 million to $100.1 million from $94.4 million in 1999. The increase was attributable primarily to enhancement of existing diagnostic platforms, an increase in sales and marketing expenses associated with the pharmaceutical product line and research and development expenses related to vetconnect.com, our Internet site for animal health professionals. Additionally, we incurred non-recurring severance and facilities expenses of $2.1 million associated with consolidation of the Internet business and the veterinary practice information management software systems business.
FOOD AND ENVIRONMENTAL DIVISION
Revenue for FED decreased $7.2 million, or 9% to $71.7 million from $78.9 million in 1999. The decrease was attributable primarily to the divestiture of the food microbiology testing business, and to a lesser extent, decreased sales of dairy testing products. These decreases were partially offset by an increase in sales of water testing products, including incremental sales resulting from the acquisition of Genera in August 2000, and increased sales of livestock test kits.
Gross profit as a percent of FED's revenue increased to 57% from 51% in 1999. The increase was primarily due to the divestiture of the lower gross margin food microbiology testing business and increased sales of higher gross margin water testing products.
Page 15
Operating expenses relating to FED decreased $7.6 million to $21.7 million from $29.3 million in 1999. The decrease was attributable primarily to the elimination of operating expenses associated with the food microbiology testing products business and to a $1.5 million gain on the sale of such business that was recorded as a decrease of expenses.
INTEREST INCOME, NET
Net interest income was $2.2 million for 2001 compared with $5.0 million during 2000. The decrease in interest income was mainly due to lower invested cash balances, as discussed below, as well as lower effective interest rates.
Net interest income was $5.0 million for 2000 compared with $5.7 million for the prior year. The decrease in interest income was principally the result of lower invested cash balances due to the use of cash for our share repurchase program and the purchase of VPS and Genera, partially offset by higher effective interest rates.
* PROVISION FOR INCOME TAXES
Our effective tax rate was 36% for 2001 compared with 37% for 2000 and 38% in 1999. The reduction in the effective tax rate was the result of continued realization of tax benefits resulting from business operations in jurisdictions with lower effective income tax rates.
* SUBSEQUENT EVENT
In January 2002, David E. Shaw, IDEXX's Founder, Chairman and Chief Executive Officer, was succeeded as Chairman and Chief Executive Officer by Jonathan W. Ayers. Under an October 2001 agreement with Mr. Shaw, we are required to make certain payments and provide certain benefits to him following a succession to a new Chief Executive Officer. As a result, we will incur in the first quarter of 2002 a pre-tax charge of approximately $3.0 million, $2.0 million of which is non-cash.
* RECENT ACCOUNTING PRONOUNCEMENTS
In July 2001, the Financial Accounting Standards Board ("FASB") issued SFAS No. 141, "Business Combinations." SFAS No. 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method.
In July 2001, the FASB issued SFAS No. 142, "Goodwill and Other Intangible Assets." We will adopt the requirements of SFAS No. 142 effective January 1, 2002. SFAS No. 142 requires companies to test all goodwill for impairment and to cease amortization of this asset. The provisions of SFAS No. 142 apply to all goodwill regardless of when it was acquired. We are evaluating the impact of adoption of this standard and have not yet determined the full effect of adoption on our financial statements. Amortization of goodwill for the year ended December 31, 2001 was $5.1 million. See "Critical Accounting Policies" above.
In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets." Adoption of the standard is required no later than the first quarter of 2002. We are evaluating the timing and impact of adoption of this standard and have not yet determined the effect of adoption on our financial statements.
* LIQUIDITY AND CAPITAL RESOURCES
At December 31, 2001, we had $79.6 million of cash, cash equivalents and short-term investments (of which $7.0 million is restricted) and working capital of $164.2 million. As of December 31, 2001, we had long-term investments of $21.0 million.
In connection with the acquisition of Genera in August 2000, we issued $8.3 million in notes payable to a former shareholder of Genera. $7.0 million of the notes are due on demand and secured by cash in escrow. $1.3 million of the notes are due in annual installments over four years and have been discounted to 6%. The former shareholder has elected to defer the first $0.5 million payment that was due in August 2001, and therefore, the deferred payment now bears interest at 3% and is due on demand.
We have entered into a $20.0 million uncommitted line of credit with a large multi-national bank. Under the terms of this agreement the bank retains the right to approve all borrowings and all borrowings are due on demand. Any borrowings under this line will bear interest at the bank's prime rate. There were no loans outstanding under this agreement at December 31, 2001.
Page 16
We purchased approximately $17.4 million in fixed assets during the year ended December 31, 2001, principally related to the CAG segment. Our total capital budget for 2002 is approximately $17.0 million. Under certain supply agreements with suppliers of veterinary instruments, slides for our VetTest instruments and certain raw materials, at December 31, 2001 we had aggregate commitments to purchase approximately $66.6 million of products in 2002.
Cash provided by operating activities was $46.4 million during 2001. Cash of $20.3 million was used to fund an increase in inventories, attributable principally to the CAG segment. These increases relate primarily to contractually required purchases of VetTest slides, inventory associated with the development of our LaserCyte hematology instrument, and inventory associated with our nitazoxanide new animal drug in registration with the FDA.
During 1999 and 2000, the Board of Directors authorized the purchase of up to ten million shares of our Common Stock in the open market or in negotiated transactions. During 2001, we repurchased 590,000 shares of our Common Stock for $13.0 million. As of December 31, 1999, 2000, and 2001, approximately 3,899,000, 7,024,000 and 7,614,000 cumulative shares, respectively, had been repurchased under this program. See Note 16 to the consolidated financial statements.
We are required to make the following payments in the years below (in thousands):
Contractual Obligations
____
Total
___
____
2002
___
__
2003-2004
_
__
2005-2006
_
_
After 2006
_
Notes payable
$ 8,380
$ 8,380
$ --
$ --
$ --
Operating leases
28,674
5,505
9,245
7,421
6,503
Unconditional purchase obligations
299,356
66,656
89,300
73,800
69,600
Total contractual cash obligations
$ 336,410
$ 80,541
$ 98,545
$ 81,221
$ 76,103
=====
=====
=====
=====
=====
We believe that current cash, short-term investments, long-term investments, debt facilities and funds generated from operations will be sufficient to fund our operations for the foreseeable future.
* FUTURE OPERATING RESULTS
The future operating results of IDEXX involve a number of risks and uncertainties. Actual events or results may differ materially from those discussed in this report. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed below as well as those discussed elsewhere in this report.
IDEXX's Future Growth Will Depend on Several Factors.
The rate of growth of sales of certain of our products has declined over the past several years. To increase our growth rate, we will need to successfully implement strategies, including:
· |
developing, manufacturing and marketing new products with new features and capabilities, including pharmaceutical |
products and a new hematology system; |
|
· |
expanding our market by increasing use of our products by our customers; |
|
|
· |
strengthening our sales and marketing activities in geographies outside of the United States; |
|
|
· |
developing and implementing new technology development and licensing strategies; and |
|
|
· |
identifying and completing acquisitions that enhance our existing businesses or create new business areas for us. |
However, we may not be able to successfully implement some or all of these strategies and increase our growth rate.
The Markets in Which IDEXX Competes Are Competitive and Subject to Rapid and Substantial Technological Change.
We face intense competition within the markets that we sell our products and services. We expect that future competition will become even more intense, and that we will have to compete with changing and improving technologies.
Page 17
Some of our competitors and potential competitors, including large pharmaceutical companies, have substantially greater capital, manufacturing, marketing and research and development resources than us.
IDEXX's Products and Services Are Subject to Various Domestic and Foreign Government Regulations.
In the U.S., the manufacture and sale of our products are regulated by agencies such as the USDA, FDA and EPA. Compliance with regulations of such government agencies can be cumbersome and expensive. For example, commercialization of animal health pharmaceuticals requires submission of substantial clinical, manufacturing and other data to the FDA. Regulatory approval for products submitted to the FDA may take several years and following approval, the FDA continues to regulate all aspects of the manufacture, labeling, storage, record keeping and promotion of pharmaceutical products.
Foreign regulatory bodies often establish product standards different from those in the United States, and designing products in compliance with such foreign standards may be difficult or expensive.
Delays in obtaining, or the failure to obtain, any necessary regulatory approvals could have a material adverse effect on our results of operations. Further, any failure to comply with regulatory requirements relating to the manufacture and sale of our products could result in fines and sanctions against us and also could have a negative effect on the sale of our products and services.
IDEXX's Future Operating Results May Be Negatively Impacted by Various Factors.
Factors such as the introduction and market acceptance of new products and services, the mix of products and services sold and the mix of domestic versus international revenue could negatively impact our future operating results.
Since we sell many of our products through distributors, changes in distributors' purchasing patterns could result in lower revenue for us because our revenue for each quarter is usually generated from orders received during that quarter. Our financial performance, therefore, is subject to an unexpected downturn in product demand and may be unpredictable.
Our expense levels are based in part on expectations of future revenue levels. Therefore, a loss in expected revenue could result in a disproportionate decrease in our net income.
IDEXX's Success Is Heavily Dependent Upon Its Proprietary Technologies.
We rely on a combination of patent, trade secret, trademark and copyright law to protect our proprietary rights. If we do not have adequate protection of our proprietary rights, our business may be affected by competitors who develop substantially equivalent technologies that compete with us.
We cannot assure that we will obtain issued patents, that any patents issued or licensed to us will remain valid, or that any patents owned or licensed by us will provide protection against competitors with similar technologies. We also cannot assure that our non-disclosure agreements will provide protection for our trade secrets and other proprietary information.
Moreover, in the past we have received notices claiming that our products infringe third-party patents and we may receive such notices in the future. Patent litigation is complex and expensive and the outcome of patent litigation can be difficult to predict. We cannot assure that we will win a patent litigation case. If we lose, we may be stopped from selling certain products and/or we may be required to pay damages as a result of the lawsuit.
IDEXX Purchases Materials for Its Products From a Limited Number of Sources.
We currently purchase certain products and materials from single sources or a limited number of sources. Some of the products that we purchase from these sources are proprietary, and therefore may not be available from other sources. These products include our chemistry and hematology analyzers and related consumables, active ingredients for pharmaceutical products and certain components of our SNAP devices. If we are unable to obtain adequate quantities of these products in the future, then we could face cost increases or reductions or delays in product shipments, which could have a material adverse effect on our results of operations.
Page 18
International Revenue Accounts for a Significant Portion of IDEXX's Total Revenue.
Various risks associated with foreign operations may impact our international sales. Possible risks include disruptions in transportation of our products, the differing product and service needs of foreign customers, difficulties in building and managing foreign operations, fluctuations in the value of foreign currencies, import/export duties and quotas, and unexpected regulatory, economic or political changes in foreign markets.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Our financial market risk consists primarily of foreign currency exchange risk. We operate subsidiaries in 13 foreign countries and transact business in local currencies. We attempt to hedge our cash flow on intercompany sales to minimize foreign currency exposure.
The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions. Corporate policy prescribes the range of allowable hedging activity. We primarily utilize forward exchange contracts and options with a duration of less than 12 months. Gains and losses related to qualifying hedges of foreign currency from commitments or anticipated transactions are deferred in prepaid expenses or accrued liabilities and are included in the basis of the underlying transaction.
Based on our overall currency rate exposure at December 31, 2001, including derivative and other foreign currency sensitive instruments, a 10% strengthening of the U.S. dollar exchange rates will reduce operating income by approximately $0.5 million and a 10% weakening of the U.S. dollar exchange rates will increase operating income by approximately $0.5 million. The effects of a 10% strengthening of the U.S. dollar exchange rates, if not offset by hedge contracts or related price adjustments, would reduce operating income by approximately $5.7 million and the effects of a 10% weakening of U.S. dollar exchange rates, if not offset by hedge contracts or related price adjustments, would increase operating income by approximately $5.7 million.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The response to this item is submitted as a separate section of this report commencing on Page F-1.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL |
DISCLOSURE |
Not Applicable.
PART III.
ITEMS 10-13.
Except as indicated below, the information required by Item 10 - Directors and Executive Officers of the Registrant; Item 11 - Executive Compensation; Item 12 - Security Ownership of Certain Beneficial Owners and Management; and Item 13 - Certain Relationships and Related Transactions, is omitted from this Annual Report on Form 10-K and, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, is incorporated herein by reference to the definitive proxy statement with respect to our 2002 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this report.
Page 19
PART IV.
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) Financial Statements and Schedules |
(1) and (2) The financial statements set forth in the Index to Consolidated Financial Statements and the Consolidated Financial |
Statement Schedule are filed as a part of this Annual Report on Form 10-K commencing on page F-1. |
(b) Reports on Form 8-K |
No reports on Form 8-K were filed during the fourth quarter of the fiscal year covered by this report. |
(a)(3) and (c) The following exhibits are filed herewith or incorporated by reference as a part of this Annual Report on Form 10-K. |
EXHIBIT INDEX
2.1(7) |
Stock Purchase Agreement dated as of September 23, 1998 |
among the Company, Blue Ridge Pharmaceuticals, Inc. ("Blue |
|
Ridge") and the stockholders of Blue Ridge. Certain schedules and |
|
exhibits to the agreement (each of which are identified in the |
|
agreement) have been omitted in reliance upon Rule 601(b)(2) of |
|
Regulation S-K. The Company hereby undertakes to furnish such |
|
schedules and exhibits to the Commission supplementally upon |
|
request. |
|
3.1(5) |
Restated Certificate of Incorporation of the Company, as amended. |
3.2(2) |
Amended and Restated By-Laws of the Company. |
4.1(1) |
Amended and Restated Rights Agreement, dated as of January 22, 2001, between the Company and American Stock Transfer & Trust Company |
as Rights Agent, which includes as Exhibit A the Form of Certificate |
|
of Designations, as Exhibit B the Form of Rights Certificate, and as Exhibit C |
|
the Summary of Rights to Purchase Preferred Stock. |
|
4.2(7) |
Form of Warrant dated October 1, 1998 to purchase Common Stock of |
the Company issued to shareholders of Blue Ridge other than |
|
employee shareholders. |
|
4.3(7) |
Form of Warrant dated October 1, 1998 to purchase Common Stock of |
the Company issued to employee shareholders of Blue Ridge. |
|
4.4 |
Instruments with respect to other long-term debt of the Company |
and its consolidated subsidiaries are omitted pursuant to Item |
|
601(b)(4)(iii) of Regulation S-K since the total amount |
|
authorized under each such omitted instrument does not exceed 10 |
|
percent of the total assets of the Company and its subsidiaries |
|
on a consolidated basis. The Company hereby agrees to furnish a |
|
copy of any such instrument to the Securities and Exchange |
|
Commission upon request. |
|
10.1(9) + |
1984 Stock Option Plan of the Company, as amended. |
**10.2 + |
1991 Stock Option Plan of the Company, as amended. |
10.3(9) + |
1991 Director Option Plan of the Company, as amended. |
10.4(3) + |
1997 Director Option Plan of the Company, as amended, with the |
form of option agreement granted thereunder attached thereto. |
|
10.5(4) + |
1997 Employee Stock Purchase Plan and 1997 International Employee Stock |
Purchase Plan. |
|
10.6(8) + |
1999 Director Stock Plan of the Company. |
*10.7(2) |
U.S. Supply Agreement, effective as of January 1, 1999, between |
the Company and Ortho-Clinical Diagnostics, Inc. ("Ortho"). |
|
|
Page 20 |
*10.8(2) |
European Supply Agreement, effective as of January 1, 1999, between the Company and Ortho. |
10.9(6) + |
Employment Agreement dated April 25, 1997 between the Company and |
Erwin F. Workman, Jr., Ph.D. |
|
**10.10 |
1998 Stock Incentive Plan of the Company, as amended. |
**10.11 + |
Amended and Restated Employment Agreement dated October 17, 2001 between |
the Company and David E.Shaw. |
|
10.12(9) + |
2000 Director Option Plan of the Company. |
**10.13 + |
Employment Agreement dated January 22, 2002 between the Company and |
Jonathan W. Ayers. |
|
**10.14 + |
Executive Employment Agreement dated January 28, 2002 between the |
Company and Jonathan W. Ayers. |
|
10.15(9) |
Form of Executive Employment Agreement dated as of May 23, 2001 |
between the Company and each of Louis W. Pollock, Robert S. Hulsy, |
|
Merilee Raines, Quentin Tonelli, S. Sam Fratoni and Conan R. Deady. |
|
**21 |
Subsidiaries of the Company. |
**23.1 |
Consent of Arthur Andersen LLP. |
**99 |
Confirmation of Arthur Andersen LLP Representations. |
__________
(1) |
Incorporated by reference to the Exhibits to the Company's Registration Statement on Form 8-A/A dated March 14, 2001 |
(File No. 000-19271). |
|
(2) |
Incorporated by reference to the Exhibits to the Company's Quarterly Report on Form 10-Q dated November 13, 2000. |
(3) |
Incorporated by reference to the Exhibits to the Company's Quarterly Report on Form 10-Q dated August 13, 1997. |
(4) |
Incorporated by reference to the Exhibits to the Company's Registration Statement on Form S-8 dated May 23, 1997. |
(5) |
Incorporated by reference to the Exhibits to the Company's Annual Report on Form 10-K dated March 28, 1997. |
(6) |
Incorporated by reference to the Exhibits to the Company's Annual Report on Form 10-K dated March 27, 1998. |
(7) |
Incorporated by reference to the Exhibits to the Company's Current Report on Form 8-K dated October 1, 1998. |
(8) |
Incorporated by reference to the Exhibits to the Company's Quarterly Report on Form 10-Q dated August 13, 1999. |
(9) |
Incorporated by reference to the Exhibits to the Company's Quarterly Report on Form 10-Q dated August 14, 2001. |
* |
Confidential treatment previously granted as to certain portions. |
** |
Filed herewith. |
+ |
Management contract or compensation plan or arrangement required to be filed as an exhibit pursuant to Item 14(d) |
of Form 10-K. |
Page 21
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:
|
IDEXX LABORATORIES, INC. |
|
|
|
|
||
By: /s/ Jonathan W. Ayers |
|||
Jonathan W. Ayers |
|||
President and Chief Executive Officer |
|||
March 21, 2002 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
SIGNATURE |
TITLE |
DATE |
|
/s/ Jonathan W. Ayers |
President, Chief Executive Officer and |
March 21, 2002 |
|
Jonathan W. Ayers |
Chairman of the Board of Directors |
||
/s/ Merilee Raines |
Vice President, Finance and |
March 21, 2002 |
|
Merilee Raines |
Treasurer (Principal Financial |
||
and Accounting Officer) |
|||
/s/ Erwin F. Workman, Jr., Ph.D. |
Executive Vice President, |
March 21, 2002 |
|
Erwin F. Workman, Jr., Ph.D. |
Chief Scientific Officer |
||
and Director |
|||
/s/ Thomas Craig |
Director |
March 21, 2002 |
|
Thomas Craig |
|||
/s/ William End |
Director |
March 21, 2002 |
|
William End |
|||
/s/ Mary L. Good |
Director |
March 21, 2002 |
|
Mary L. Good |
|||
/s/ John R. Hesse |
Director |
March 21, 2002 |
|
John R. Hesse |
|||
/s/ James L. Moody, Jr. |
Director |
March 21, 2002 |
|
James L. Moody, Jr. |
|||
/s/ William F. Pounds |
Director |
March 21, 2002 |
|
William F. Pounds |
Page 22
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENT |
SCHEDULE |
PAGE |
|
* Report of Independent Public Accountants |
F-2 |
* Consolidated Balance Sheets as of December 31, 2000 and 2001 |
F-3 |
* Consolidated Statements of Operations for the Years Ended December 31, |
|
1999, 2000 and 2001 |
F-4 |
* Consolidated Statements of Stockholders' Equity for the Years Ended |
|
December 31, 1999, 2000 and 2001 |
F-5 |
* Consolidated Statements of Cash Flows for the Years Ended December 31, |
|
1999, 2000 and 2001 |
F-6 |
* Notes to Consolidated Financial Statements |
F-7 |
* Schedule II |
|
Valuation and Qualifying Accounts |
F-23 |
Page F-1
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Stockholders and Board of Directors of IDEXX Laboratories, Inc.:
We have audited the accompanying consolidated balance sheets of IDEXX Laboratories, Inc. (a Delaware corporation) and subsidiaries as of December 31, 2000 and 2001, and the related consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2001. These consolidated financial statements and the schedule referred to below are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing standards in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of IDEXX Laboratories, Inc. and subsidiaries as of December 31, 2000 and 2001, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001, in conformity with generally accepted accounting principles in the United States.
Our audits were made for the purpose of forming an opinion on the basic consolidated financial statements taken as a whole. The schedule listed in the index to consolidated financial statements is presented for purposes of complying with the Securities and Exchange Commission's rules and is not part of the basic consolidated financial statements. The schedule has been subjected to the auditing procedures applied in the audits of the basic consolidated financial statements and, in our opinion, fairly states, in all material respects, the financial data required to be set forth therein in relation to the basic consolidated financial statements taken as a whole.
/s/ ARTHUR ANDERSEN LLP |
|
Boston, Massachusetts |
|
January 24, 2002 |
Page F-2
IDEXX LABORATORIES, INC. AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS |
(in thousands, except per share data) |
__ ___DECEMBER 31,__ ___ |
||
_ __2000___ |
_ __2001___ |
|
ASSETS |
||
Current Assets: |
||
Cash and cash equivalents, $6,952 was restricted in 2000 |
||
and $6,996 is restricted in 2001 |
$ 46,007 |
$ 66,666 |
Short-term investments |
29,196 |
12,893 |
Accounts receivable, less reserves of $4,390 in 2000 and |
||
$3,993 in 2001 |
57,266 |
50,772 |
Inventories |
65,935 |
86,194 |
Deferred income taxes |
12,738 |
14,239 |
Other current assets |
4,688 |
4,812 |
Total current assets |
215,830 |
235,576 |
Long-Term Investments (Note 3) |
-- |
21,016 |
Property and Equipment, at cost: |
||
Land |
1,190 |
1,189 |
Buildings |
4,570 |
5,011 |
Leasehold improvements |
19,138 |
19,566 |
Machinery and equipment |
37,785 |
45,242 |
Construction in progress |
2,029 |
5,991 |
Office furniture and equipment |
33,440 |
31,703 |
98,152 |
108,702 |
|
Less -- Accumulated depreciation and amortization |
52,491 |
59,487 |
45,661 |
49,215 |
|
Other Assets, net |
74,305 |
67,300 |
$ 335,796 |
$ 373,107 |
|
======== |
======== |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
||
Current Liabilities: |
||
Accounts payable |
$ 13,714 |
$ 10,887 |
Accrued expenses |
39,908 |
38,890 |
Notes payable |
8,472 |
8,380 |
Deferred revenue |
11,955 |
13,220 |
Total current liabilities |
74,049 |
71,377 |
Commitments and Contingencies (Note 5) |
||
Stockholders' Equity: |
||
Preferred Stock, $1.00 par value -- Authorized -- 500 shares |
||
None issued and outstanding |
-- |
-- |
Series A Junior Participating Preferred Stock, $1.00 par value |
||
Designated -- 100 shares of Preferred Stock |
||
None issued and outstanding |
-- |
-- |
Common stock, $0.10 par value -- Authorized -- 60,000 shares |
||
issued 40,255 shares in 2000 and 41,354 shares in 2001 |
4,025 |
4,135 |
Additional paid-in capital |
296,914 |
313,883 |
Retained earnings |
100,251 |
137,871 |
Accumulated other comprehensive loss |
(4,964) |
(6,694) |
Treasury stock (7,024 shares in 2000 and 7,614 shares in 2001), |
||
at cost |
(134,479 ) |
(147,465 ) |
Total stockholders' equity |
261,747 |
301,730 |
$ 335,796 |
$ 373,107 |
|
======== |
======== |
The accompanying notes are an integral part of these consolidated financial statements.
Page F-3
IDEXX LABORATORIES, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF OPERATIONS |
(in thousands, except per share data) |
____ ____YEARS ENDED DECEMBER 31,____ ____ |
|||
__ __ 1999_____ |
____2000_____ |
____2001_____ |
|
Revenue |
$ 358,370 |
$ 367,432 |
$ 386,081 |
Cost of revenue |
186,386 |
190,256 |
202,750 |
Gross profit |
171,984 |
177,176 |
183,331 |
Expenses: |
|||
Sales and marketing |
53,885 |
54,956 |
57,087 |
General and administrative |
43,969 |
40,677 |
41,266 |
Research and development |
27,313 |
28,292 |
28,426 |
Income from operations |
46,817 |
53,251 |
56,552 |
Interest income, net |
5,728 |
4,996 |
2,229 |
Net income before provision for |
|||
income taxes |
52,545 |
58,247 |
58,781 |
Provision for income taxes |
19,967 |
21,615 |
21,161 |
Net income |
$ 32,578 |
$ 36,632 |
$ 37,620 |
|
======== |
======== |
======== |
Earnings per share: Basic |
$ 0.85 |
$ 1.06 |
$ 1.13 |
|
======== |
======== |
======== |
Earnings per share: Diluted |
$ 0.82 |
$ 1.02 |
$ 1.09 |
|
======== |
======== |
======== |
Weighted average shares outstanding: Basic |
38,412 |
34,574 |
33,293 |
|
======== |
======== |
======== |
Weighted average shares outstanding: Diluted |
39,743 |
36,081 |
34,640 |
|
======== |
======== |
======== |
The accompanying notes are an integral part of these consolidated financial statements.
Page F-3
IDEXX LABORATORIES, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY |
(in thousands, except per share data) |
_____COMMON STOCK____ |
|||||||
ACCUMULATED |
|||||||
ADDITIONAL |
OTHER |
TOTAL |
|||||
NUMBER |
$0.10 |
PAID-IN |
RETAINED |
COMPREHENSIVE |
TREASURY |
STOCKHOLDERS' |
|
OF SHARES |
PAR VALUE |
__CAPITAL__ |
EARNINGS |
_INCOME (LOSS)_ |
__STOCK__ |
_____EQUITY_____ |
|
BALANCE, December 31, 1998 |
38,831 |
$ 3,883 |
$ 276,296 |
$ 31,041 |
$ (3,380) |
$ -- |
$ 307,840 |
Issuance of common stock to |
|||||||
Board of Directors |
13 |
1 |
342 |
-- |
-- |
-- |
343 |
Purchase of treasury stock |
-- |
-- |
-- |
-- |
-- |
(64,222) |
(64,222) |
Exercise of stock options, |
|||||||
including the tax benefit |
740 |
74 |
7,821 |
-- |
-- |
-- |
7,895 |
Comprehensive income (loss): |
|||||||
Net income |
-- |
-- |
-- |
32,578 |
-- |
-- |
-- |
Translation adjustment |
-- |
-- |
-- |
-- |
(93) |
-- |
-- |
Total comprehensive income |
-- |
-- |
-- |
-- |
-- |
-- |
32,485 |
BALANCE, December 31, 1999 |
39,584 |
3,958 |
284,459 |
63,619 |
(3,473) |
(64,222) |
284,341 |
Issuance of common stock to |
|||||||
Board of Directors |
1 |
-- |
10 |
-- |
-- |
-- |
10 |
Purchase of treasury stock |
-- |
-- |
-- |
-- |
-- |
(70,257) |
(70,257) |
Exercise of stock options, |
|||||||
including the tax benefit |
670 |
67 |
12,445 |
-- |
-- |
-- |
12,512 |
Comprehensive income (loss): |
|||||||
Net income |
-- |
-- |
-- |
36,632 |
-- |
-- |
-- |
Translation adjustment |
-- |
-- |
-- |
-- |
(1,491) |
-- |
-- |
Total comprehensive income |
-- |
-- |
-- |
-- |
-- |
-- |
35,141 |
BALANCE, December 31, 2000 |
40,255 |
4,025 |
296,914 |
100,251 |
(4,964) |
(134,479) |
261,747 |
Purchase of treasury stock |
-- |
-- |
-- |
-- |
-- |
(12,986) |
(12,986) |
Exercise of stock options, |
|||||||
including the tax benefit |
984 |
99 |
16,980 |
-- |
-- |
-- |
17,079 |
Shares issued in connection with |
|||||||
Blue Ridge acquisition |
115 |
11 |
(11) |
-- |
-- |
-- |
-- |
Comprehensive income (loss): |
|||||||
Net income |
-- |
-- |
-- |
37,620 |
-- |
-- |
-- |
Unrealized gain on investments, |
|||||||
net of tax |
-- |
-- |
-- |
-- |
44 |
-- |
-- |
Unrealized net loss on forward |
|||||||
exchange contracts, net of tax |
-- |
-- |
-- |
-- |
(266) |
-- |
-- |
Translation adjustment |
-- |
-- |
-- |
-- |
(1,508) |
-- |
-- |
Total comprehensive income |
-- |
-- |
-- |
-- |
-- |
-- |
35,890 |
BALANCE, December 31, 2001 |
41,354 |
$ 4,135 |
$ 313,883 |
$ 137,871 |
$ (6,694) |
$ (147,465) |
$ 301,730 |
|
===== |
======= |
======== |
======== |
======== |
======== |
======== |
The accompanying notes are an integral part of these consolidated financial statements.
Page F-5
IDEXX LABORATORIES, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF CASH FLOWS |
(in thousands) |
|
__________YEARS ENDED DECEMBER 31,__________ |
||
|
_____1999_____ |
_____2000_____ |
_____2001_____ |
Cash Flows From Operating Activities: |
|||
Net income |
$ 32,578 |
$ 36,632 |
$ 37,620 |
Adjustments to reconcile net income to net |
|||
cash provided by operating activities |
|||
Depreciation and amortization |
17,209 |
19,481 |
22,229 |
Provision for (benefit of) deferred income tax |
2,019 |
3,098 |
(380) |
Changes in assets and liabilities, net of |
|||
acquisitions and disposals |
|||
Accounts receivable |
(10,406) |
1,077 |
5,554 |
Inventories |
5,182 |
(28,506) |
(20,319) |
Other current assets |
1,169 |
1,869 |
(407) |
Accounts payable |
(7,169) |
(8,534) |
(2,750) |
Accrued expenses |
10,058 |
1,436 |
3,484 |
Deferred revenue |
1,979 |
1,687 |
1,333 |
Net cash provided by operating activities |
52,619 |
28,240 |
46,364 |
Cash Flows From Investing Activities: |
|||
Decrease (increase) in investments, net |
(25,765) |
43,156 |
(4,639) |
Purchases of property and equipment |
(8,292) |
(15,520) |
(17,381) |
Increase in other assets |
(1,229) |
(1,866) |
(4,210) |
Proceeds from sale of businesses |
350 |
10,400 |
-- |
Acquisition(s) of business(es), net of |
|||
cash acquired |
(4,088 ) |
(11,945 ) |
-- |
Net cash provided (used) by investing activities |
(39,024 ) |
24,225 |
(26,230) |
Cash Flows From Financing Activities: |
|||
Repayment of notes payable |
(6,411) |
(3,322) |
(144) |
Purchase of treasury stock |
(64,222) |
(70,257) |
(12,986) |
Proceeds from the exercise of stock options |
6,611 |
10,229 |
14,044 |
Net cash provided (used) by financing activities |
(64,022 ) |
(63,350 ) |
914 |
Net Effect of Exchange Rate Changes |
(60 ) |
(1,684 ) |
(389 ) |
Net Increase (Decrease) in Cash and Cash Equivalents |
(50,487) |
(12,569) |
20,659 |
Cash and Cash Equivalents, Beginning of Year |
109,063 |
58,576 |
46,007 |
Cash and Cash Equivalents, End of Year |
$ 58,576 |
$ 46,007 |
$ 66,666 |
|
======== |
======== |
======== |
Supplemental Disclosure of Cash Flow Information: |
|||
Interest paid during the year |
$ 405 |
$ 361 |
$ 79 |
|
======== |
======== |
======== |
Income taxes paid during the year |
$ 12,827 |
$ 12,966 |
$ 19,476 |
|
======== |
======== |
======== |
Supplemental Disclosure of Non-cash Investing and |
|||
Financing Activity: |
|||
Receipt of note for sale of businesses |
$ 195 |
$ 450 |
$ -- |
|
======== |
======== |
======== |
Issuance of notes for acquisition of Genera Technologies |
|||
Ltd. |
$ -- |
$ 8,277 |
$ -- |
|
======== |
======== |
======== |
The accompanying notes are an integral part of these consolidated financial statements.
Page F-6
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
IDEXX Laboratories, Inc. and subsidiaries (the "Company") develop, manufacture and distribute products and provide services for the veterinary, food and environmental markets. In the veterinary market, the Company develops, manufactures and distributes biology-based detection systems, develops and distributes veterinary pharmaceuticals and chemistry-based detection systems, provides laboratory testing and specialized consulting services and develops and distributes veterinary practice information management software systems and provides related services. In the food and environmental market, the Company develops, manufactures and distributes biology-based detection systems. The Company's products and services are sold worldwide.
The accompanying consolidated financial statements reflect the application of certain significant accounting policies, as discussed below and elsewhere in the notes to the consolidated financial statements. The preparation of these consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
(a) Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All material intercompany transactions and balances have been eliminated in consolidation.
(b) Inventories
Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out) or market. The Company writes down inventory for estimated obsolescence based upon assumptions about future demand and market conditions, which may negatively affect the Company's ability to dispose of inventory. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which would have a negative effect on the Company's results of operations.
The Company's inventories as of December 31, 2001 included $8.6 million of raw materials associated with the nitazoxanide product in registration with the FDA, of which $8.4 million will expire and become unusable in 2004 and the remainder has no expiration date. The Company has completed manufacturing and efficacy components of its submission to the FDA. The Company has completed additional safety studies requested by the FDA with respect to this product and is preparing a submission reporting the results of these studies. The Company believes that the product is approvable by the FDA and that this inventory will be saleable upon such approval. If this product is not approved by the FDA, the Company believes that it has the ability to recoup a substantial portion of its costs through alternative future uses of the material or other means. The Company has provided reserves to cover estimated potential losses in this scenario. However, the Company cannot provide assurance that the FDA will approve this product or if such approval is not obtained, that its current estimates of recovery of its investment in this inventory will not change.
The Company's inventories include $30.4 million of slides used in its chemistry instruments, which represent approximately 1.3 turns based on recent historical usage. These slides have a shelf life of 24 months at the date of manufacture. The average remaining shelf life at December 31, 2001 was 16.5 months. In addition, the Company is required to purchase $289.0 million of slides over the remaining nine years of the contract with Ortho. The Company believes the demand for these slides is at a level sufficient to ensure that it will not incur a loss on the inventory or the contract. However, a reduction in the demand for slides could cause the Company to incur a loss related to its slide inventory or purchase commitments at a future date.
The Company's inventories include $6.0 million of component parts associated with its LaserCyte hematology instrument, which is in the final stages of development. In addition, the Company has placed $0.9 million in deposits with vendors to secure additional critical components and has firm purchase commitments of an additional $6.2 million. The Company expects to launch this product in the second half of 2002 and to fully realize its investment and purchase commitments. However, if the Company is unable to introduce this product, or if the Company alters the final design, it may be required to write-off a certain amount of the associated inventory.
Page F-7
The components of inventories are as follows (in thousands):
____DECEMBER 31,_____
___2000___
___2001___
Raw materials
$ 14,857
$ 18,414
Work-in-process
3,513
4,691
Finished goods
47,565
63,089
$ 65,935
$ 86,194
========
========
(c) Depreciation and Amortization
The Company provides for depreciation and amortization using the declining-balance and straight-line methods by charges to operations in amounts that allocate the cost of property and equipment over their estimated useful lives as follows:
|
ESTIMATED |
ASSET CLASSIFICATION________ |
USEFUL LIFE
|
Leasehold improvements |
Life of lease |
Machinery and equipment |
3-5 Years |
Office furniture and equipment |
3-7 Years |
Buildings |
40 Years |
(d) Other Assets
Other assets are as follows (in thousands):
______DECEMBER 31,___
DESCRIPTION____________
USEFUL LIFE
___2000___
_ __ 2001___
Patents
15 Years
$ 3,136
$ 3,051
Goodwill
5-40 Years
81,480
80,735
Non-compete agreements
5-10 Years
2,280
280
Other intangibles
5-10 Years
4,203
4,240
91,099
88,306
Accumulated amortization
(29,138
)
(33,098
)
Intangible assets, net
61,961
55,208
Deferred tax asset
5,778
4,657
Cost basis from lease
arrangements
3 Years
4,688
5,507
Other assets
1,878
1,928
$ 74,305
$ 67,300
========
========
The Company assesses the impairment of identifiable intangibles, long-lived assets and goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers important that could trigger an impairment review include, but are not limited to, the following:
· significant under-performance relative to historical or projected future operating results;
· significant changes in the manner of our use of the acquired assets or the strategy for our overall business; and
· significant negative industry or economic trends.
When management determines that the carrying value of intangibles, long-lived assets and goodwill may not be recoverable based on a change in events and circumstances discussed above, the Company measures any impairment based on the projected undiscounted cash flow method. Net intangible assets and goodwill amounted to $55.2 million as of December 31, 2001, consisting of $24.3 million related to veterinary reference laboratories, $15.0 million related to water test products, $14.6 million related to pharmaceutical products and $1.3 million of other.
In 2002, Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets" ("SFAS No. 142"), became effective and as a result, the Company will cease to amortize approximately $50.9 million of goodwill. The Company had recorded approximately $5.1 million of amortization on these amounts during 2001 and would have recorded approximately $4.3 million of amortization during 2002 if the existing standards had been continued. In lieu of amortization, management is required to perform an initial impairment review of the Company's goodwill in 2002 and an annual impairment review thereafter. Management expects to complete its initial review during the first half of 2002.
Page F-8
The Company currently does not expect to record an impairment charge upon completion of the initial impairment review. However, there can be no assurance that at the time the review is completed a material impairment charge will not be recorded.
Other intangibles include subscriber lists, existing technology, intangible assets, and prepaid license fees. Amortization of intangible assets was $7.5 million, $7.9 million and $6.5 million for the years ended December 31, 1999, 2000 and 2001, respectively. The Company continually assesses the realizability of these assets in accordance with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets To Be Disposed Of". As of the respective balance sheet dates, the Company determined that no impairment has occurred.
(e) Stock-Based Compensation Plans
The Company measures compensation related to stock-based compensation plans under the provisions of SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS No. 123"). Under SFAS No. 123, the Company elected the disclosure only method and will continue to account for stock-based compensation plans under Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees". See Note 7.
(f) Income Taxes
The Company accounts for income taxes under SFAS No. 109, "Accounting for Income Taxes". This statement requires that the Company recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. See Note 2.
(g) Revenue Recognition
The Company recognizes product revenue at the time of shipment (including to distributors) for substantially all products, except software licenses and hardware systems. The Company recognizes revenue from non-cancelable software licenses and hardware systems upon installation and customer acceptance of the software because at this time collection is probable and the Company has no significant further obligations after installation. The Company's distributors do not have the right to return products. Service revenue is recognized at the time the service is performed. Maintenance revenue is billed in advance and recognized over the life of the contracts, usually one year or less. Certain instrument systems are sold to a third-party finance company that leases these systems to its customers with a right-of-return privilege. The Company allows the third-party finance company to return these instruments for a partial refund based on the time from product return to end of lease term. Therefore the Company recognizes revenue under these contracts over the term of the underlying customer lease contract. The Company leases certain instruments directly to customers and recognizes revenues from those leases over the terms of those leases. The Company records estimated reductions to revenue in connection with customer programs and incentive offerings, which may give customers future rights such as free or discounted goods or services or trade-in rights.
In December 1999, the Securities and Exchange Commission issued Staff Accounting Bulletin ("SAB") No. 101. SAB No. 101 provides guidance on selected revenue recognition issues. The Company adopted the provisions of SAB No. 101 during 2000. The adoption of SAB No. 101 did not have a material impact on the financial statements of the Company.
(h) Research and Development and Software Development Costs
In accordance with SFAS No. 86, "Accounting for the Costs of Computer Software to be Sold, Leased or Otherwise Marketed", the Company has evaluated the establishment of technological feasibility of its various products during the development phase. Due to the dynamic changes in the market, the Company has concluded that it cannot determine technological feasibility until the development phase of the project is nearly complete. The Company charges all research and development expenses to operations in the period incurred as the costs from the point of technological feasibility to first product release are immaterial.
Page F-9
(i) Foreign Currency Translation
Assets and liabilities of the Company's foreign subsidiaries are translated using the exchange rate in effect at the balance sheet date. Revenue and expense accounts are translated using a weighted average of exchange rates in effect during the period. Cumulative translation gains and losses are shown in the accompanying consolidated balance sheets as a separate component of accumulated other comprehensive income (loss). Exchange gains and losses arising from transactions denominated in foreign currencies other than the functional currency of the entity entering into the transaction are included in current operations. Included in general and administrative expenses are foreign currency translation losses of $0.3 million, $0.6 million and $0.6 million for the years ended December 31, 1999, 2000 and 2001, respectively.
(j) Derivative Instruments and Hedging
Effective in the first quarter of 2001, the Company adopted SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS No. 133"). SFAS No. 133, as amended, requires that all derivatives, including forward currency exchange contracts, be recognized on the balance sheet at fair value. Derivatives that are not hedges must be recorded at fair value through earnings. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive income until the hedged item is recognized in earnings. The Company immediately records in earnings the extent to which a hedge is not effective in achieving offsetting changes in fair value. The adoption of SFAS No. 133 in the first quarter of 2001 was not material.
The Company enters into foreign currency exchange contracts of its anticipated intercompany and third-party inventory purchases for the next twelve months in order to minimize the impact of foreign currency fluctuations on these transactions. The Company's accounting policies for these contracts are based on the Company's designation of such instruments as hedging transactions. The Company also utilizes some natural hedges to mitigate its transaction and commitment exposures. The contracts the Company enters into are firm foreign currency commitments, and therefore market gains and losses are deferred until the contract matures, which is the period when the related obligation is settled. The Company enters into these exchange contracts with large multi-national financial institutions. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. The Company hedges less than the full value of forecasted sales and thus no ineffectiveness has resulted or been recorded through the statement of operations. As of December 31, 2000, there were no material unrecorded gains or losses. As of December 31, 2001, the Company recorded $0.4 million in losses through accumulated other comprehensive loss from foreign exchange contracts with 2002 expiration dates. The forward foreign currency contracts, which extend through December 31, 2001 and 2002, respectively, consisted of the following notional amounts (in thousands):
__CURRENCY SOLD__
_____US DOLLAR EQUIVALENT___
_ ____2000______
__ ___2001______
Euro
$ 18,474
$ 16,946
British Pound
12,927
12,448
Canadian Dollar
4,398
6,716
Australian Dollar
1,716
1,396
Japanese Yen
1,850
1,593
Taiwan Dollar
--
1,070
$ 39,365
$ 40,169
========
========
Gains and losses on foreign exchange contracts intended as hedges for intercompany sales of goods are recorded in cost of sales. Included in cost of goods sold are foreign exchange gains of $0.9 million, $2.7 million and $1.4 million for the years ended December 31, 1999, 2000 and 2001, respectively.
(k) Disclosure of Fair Value of Financial Instruments and Concentration of Credit Risk
Financial instruments consist mainly of cash and cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payables, notes payable and forward currency contracts. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. The Company places its investments in highly rated financial institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Short-term investments, long-term investments, and forward currency contracts are marked to fair market value through accumulated other comprehensive loss. The carrying amounts of the Company's other financial instruments approximate fair market value.
Page F-10
(l) Earnings per Share
Basic earnings per share is computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The following is a reconciliation of shares outstanding for basic and diluted earnings per share (in thousands):
_1999_
_2000_
_2001_
Shares Outstanding For Basic Earnings Per Share:
Weighted average shares outstanding
38,412
34,574
33,293
Shares Outstanding For Diluted Earnings Per Share:
Weighted average shares outstanding
38,412
34,574
33,293
Shares assumed issued for the acquisition of Blue Ridge Pharmaceuticals, Inc.
115
115
65
Dilutive effect of options issued to employees
1,216
1,392
1,282
39,743
36,081
34,640
===
===
===
===
===
===
Options to purchase 1,294,000, 934,000 and 306,000 shares for 1999, 2000 and 2001, respectively, have been excluded from the calculation of shares outstanding for diluted earnings per share because they were antidilutive.
(m) Reclassifications
Reclassifications have been made in the consolidated financial statements to conform to the current year's presentation.
(n) Comprehensive Income
SFAS No. 130, "Reporting Comprehensive Income", requires companies to report all changes in equity during a period, resulting from net income and transactions or other events and circumstances from non-owner sources, in a financial statement for the period in which they are recognized. The Company has chosen to disclose comprehensive income, which encompasses net income, foreign currency translation adjustments and the difference between the cost and the fair market value of investments in debt securities and foreign exchange contracts, in the Consolidated Statement of Stockholders' Equity. The Company considers the foreign currency cumulative translation adjustment to be permanently invested and therefore has not provided income taxes on those amounts.
(o) New Accounting Standards
In July 2001, the Financial Accounting Standards Board ("FASB") issued SFAS No. 141, "Business Combinations." ("SFAS No. 141"). SFAS No. 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method.
In July 2001, the FASB issued SFAS No. 142. The Company will adopt the requirements of SFAS No. 142 effective January 1, 2002. SFAS No. 142 requires companies to test all goodwill for impairment and to cease amortization of this asset. The provisions of SFAS No. 142 apply to all goodwill regardless of when it was acquired. See Note 1(d).
In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets." Adoption of the standard is required no later than the first quarter of 2002. The Company is evaluating the timing and impact of adoption of this standard and has not yet determined the effect of adoption on its financial statements.
(p) Allowance for Doubtful Accounts Receivable
The Company maintains allowances for doubtful accounts receivable for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.
Page F-11
(q) Warranty Reserves
The Company provides for the estimated cost of product warranties at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Should actual product failure rates or service delivery costs differ from management's estimates, which are based on historical data and engineering estimates where applicable, revisions to the estimated warranty liability would be required.
In the second half of 2002, the Company expects to introduce the LaserCyte system. The Company expects that sales of this system will cause warranty expense to increase significantly in 2002. The Company will charge warranty expense to the cost of LaserCyte sales based on its experience with instrument sales and engineering information about the system. Should actual warranty expense exceed the Company's estimates, the Company's cost of sales of LaserCyte systems would increase.
(2) INCOME TAXES
Earnings before income taxes for each year were as follows (in thousands):
___1999__ |
___2000__ |
___2001__ |
||
Domestic |
$ 37,253 |
$ 43,155 |
$ 46,027 |
|
International |
15,292 |
15,092 |
12,754 |
|
$ 52,545 |
$ 58,247 |
$ 58,781 |
||
======== |
======== |
======== |
The provisions for income taxes for the years ended December 31, 1999, 2000 and 2001 are comprised of the following (in thousands):
____________DECEMBER 31,____________
____1999___
____2000___
____2001___
Current
Federal
$ 10,630
$ 12,056
$ 15,325
State
3,066
3,174
3,510
International
4,252
3,287
2,706
17,948
18,517
21,541
Deferred
Federal
1,955
2,729
(133)
State
64
369
(247
)
2,019
3,098
(380
)
$ 19,967
$ 21,615
$ 21,161
========
========
========
The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate as follows:
__________DECEMBER 31,________
___1999__
___2000__
___2001__
U.S. federal statutory rate
35.0%
35.0%
35.0%
State income tax, net of federal
tax benefit
5.0
4.0
3.6
International income taxes
(2.1)
(3.2)
(3.0)
Amortization of non-deductible
assets
2.2
1.6
1.6
Non-taxable interest income
(2.9)
(1.6)
(0.8)
Other, net
0.8
1.3
(0.4
)
Effective tax rate
38.0%
37.1%
36.0%
===
===
===
Page F-12
The components of the domestic net deferred tax asset (liability) included in the accompanying consolidated balance sheets are as follows (in thousands):
___________2000__________
___________2001__________
CURRENT
LONG-TERM
CURRENT
LONG-TERM
ASSETS:
Accrued expenses
$ 4,534
$ --
$ 5,088
$ --
Receivable reserves
2,173
--
2,065
--
Deferred revenue
4,162
--
4,398
--
Inventory basis differences
2,396
--
4,248
--
Intangible basis differences
--
5,527
--
4,305
Property based differences
--
301
--
236
Net operating loss carryforwards
1,139
90
99
116
Total assets
14,404
5,918
15,898
4,657
LIABILITIES:
Cost basis from lease
arrangements
(1,666)
--
(1,659)
--
Other
--
(140
)
--
--
Total liabilities
(1,666
)
(140
)
(1,659
)
--
Net domestic deferred tax assets
$ 12,738
$ 5,778
$ 14,239
$ 4,657
=======
=======
=======
=======
The components of the foreign net deferred tax asset (in thousands):
___________2000__________
___________2001__________
CURRENT
LONG-TERM
CURRENT
LONG-TERM
ASSETS:
Net operating loss carryforwards
$ --
$ 1,663
$ --
$ 1,275
Other
--
--
--
--
Total assets
--
1,663
--
1,275
LIABILITIES:
Total liabilities
--
--
--
--
VALUATION ALLOWANCE
--
(1,663
)
--
(1,275
)
Net international deferred
tax assets
$ --
$ --
$ --
$ --
=======
=======
=======
=======
At December 31, 2001, the Company had domestic net operating loss carryforwards of approximately $0.6 million available to offset future taxable income. Net operating loss carryforwards expire at various dates through 2014. The Tax Reform Act of 1986 contains provisions that limit annual availability of the net operating loss carryforwards due to a more than 50% change in ownership that occurred upon the acquisition of certain companies.
At December 31, 2001, the Company had net operating loss carryforwards in foreign subsidiaries of approximately $3.6 million available to offset future taxable income. These net operating loss carryforwards expire at various dates beginning in 2003. The Company has recorded a valuation allowance for the assets because realizability is uncertain.
At December 31, 2001, unremitted earnings in subsidiaries outside the United States totaled $30.4 million, on which no United States taxes have been provided. The Company's intention is to reinvest these earnings permanently or to repatriate the earnings only when tax effective to do so. It is not practical to estimate the amount of additional taxes that might be payable upon repatriation of foreign earnings; however, the Company believes that United States foreign tax credits would largely eliminate any United States taxes or offset any foreign withholding taxes.
(3) CASH EQUIVALENTS, SHORT-TERM AND LONG-TERM INVESTMENTS
Cash equivalents are short-term, highly liquid investments purchased with original maturities of less than three months.
Page F-13
The Company accounts for investments under SFAS No. 115, "Accounting for Certain Investments in Debt and Equity Securities" as available-for-sale. Short-term investments are investment securities with maturities of greater than three months but less than one year and consist of the following (in thousands):
_____DECEMBER 31,____
___2000___
___2001___
Municipal bonds
$ 14,840
$ 12,893
Preferred stocks
9,642
--
U.S. government obligations
2,000
--
Certificates of deposit
2,714
--
$ 29,196
$ 12,893
========
========
Long-term investments are investment securities with maturities of greater than one year and less than five years and consist of the following (in thousands):
_____DECEMBER 31,____
___2000___
___2001___
Municipal bonds
$ --
$ 16,951
U.S. government obligations
--
4,065
$ --
$ 21,016
=====
=====
(4) NOTES PAYABLE
In September 2001, the Company entered into a $20.0 million uncommitted line of credit with a large multi-national bank. Under the terms of the agreement, the bank retains the right to approve all borrowings and all borrowings are due on demand. Borrowings will bear interest at the bank's prime rate. There were no amounts outstanding under this agreement at December 31, 2001.
In connection with the acquisition of the business of Genera Technologies Limited in August 2000, the Company issued notes payable to the former principal shareholder for $8.3 million of which $7.0 million is secured by cash in escrow. The secured portion bears interest at the same rate earned by cash in escrow. The secured portion is considered a current liability as the note holder has the right to call the payable at any time. The unsecured portion is non-interest bearing and is discounted to yield at 6% and is due in four annual installments beginning in August 2001. The note holder elected to defer the August 2001 payment, which now bears interest at 3%. This payment is now payable on demand.
In connection with the Central Veterinary Diagnostic Laboratory acquisition, the Company issued an unsecured note payable for Australian Dollars $0.9 million (US $0.6 million). The note bore interest at 6% and the final installment was paid on December 3, 2001.
In connection with the Blue Ridge Pharmaceuticals, Inc. ("Blue Ridge") acquisition (see Note 13(c)), the Company issued unsecured notes payable for $7.8 million. The notes bore interest at 6%, and the final installment was paid on September 30, 2000.
(5) COMMITMENTS AND CONTINGENCIES
The Company leases its facilities under operating leases which expire through 2012. In addition, the Company is responsible for the real estate taxes and operating expenses related to these facilities. The Company also has lease commitments for automobiles and office equipment. Minimum annual rental payments under these agreements are as follows (in thousands):
YEARS ENDING
DECEMBER 31,
2002
$ 5,505
2003
4,911
2004
4,334
2005
3,896
2006
3,525
Thereafter
6,503
$ 28,674
========
Rent expense charged to operations under operating leases was approximately $5.1 million, $5.6 million and $5.6 million for the years ended December 31, 1999, 2000 and 2001, respectively.
Page F-14
Under the terms of certain supply agreements with suppliers of the Company's veterinary instruments, slides for its VetTest instruments, and certain raw materials, the Company has aggregate commitments to purchase approximately $299.4 million of products through 2010.
From time to time the Company has received notices alleging that the Company's products infringe third-party proprietary rights. In particular, the Company has received notices claiming that certain of the Company's immunoassay products infringe third-party patents, although the Company is not aware of any pending litigation with respect to such claims. Patent litigation frequently is complex and expensive, and the outcome of patent litigation can be difficult to predict. There can be no assurance that the Company will prevail in any infringement proceedings that have been or may be commenced against the Company.
(6) STOCKHOLDERS' EQUITY
(a) Preferred Stock
The Board of Directors is authorized, subject to any limitations prescribed by law, without further stockholder approval, to issue from time to time up to 500,000 shares of Preferred Stock, $1.00 par value per share ("Preferred Stock"), in one or more series. Each such series of Preferred Stock shall have such number of shares, designations, preferences, voting powers, qualifications and special or relative rights or privileges as shall be determined by the Board of Directors, which may include, among others, dividend rights, voting rights, redemption and sinking fund provisions, liquidation preferences, conversion rights and preemptive rights.
(b) Series A Junior Participating Preferred Stock
On December 17, 1996, the Company designated 100,000 shares of Preferred Stock as Series A Junior Participating Preferred Stock ("Series A Stock") in connection with its Shareholder Rights Plan. See Note 8. In general, each share of Series A Stock will: (i) be entitled to a minimum preferential quarterly dividend of $10 per share and to an aggregate dividend of 1,000 times the dividend declared per share of Common Stock, (ii) in the event of liquidation, be entitled to a minimum preferential liquidation payment of $1,000 per share (plus accrued and unpaid dividends) and to an aggregate payment of 1,000 times the payment made per share of Common Stock, (iii) have 1,000 votes, voting together with the Common Stock, (iv) in the event of any merger, consolidation or other transaction in which Common Stock is exchanged, be entitled to receive 1,000 times the amount received per share of Common Stock and (v) not be redeemable. These rights are protected by customary antidilution provisions. There are no shares of Series A Stock outstanding.
(7) STOCK-BASED COMPENSATION PLANS
At December 31, 2001, the Company had six stock-based compensation plans, which are described below. The Company measures compensation related to these plans under the provisions of SFAS No. 123. Under SFAS No. 123 the Company elected the disclosure method and will continue to account for stock-based compensation plans under APB Opinion No. 25. Accordingly, no compensation cost has been recognized for these plans. Had compensation cost for the Company's six stock-based compensation and employee stock purchase plans been determined consistent with the provisions of SFAS No. 123, the Company's net income and net income per common and common equivalent share would have been reduced to the following pro forma amounts (shares in thousands):
_______YEARS ENDED DECEMBER 31,______
____1999____
____2000____
____2001____
Net income:
As reported
$ 32,578
$ 36,632
$ 37,620
Pro forma
25,550
31,543
32,214
Net income per share:
Basic: as reported
$ 0.85
$ 1.06
$ 1.13
Basic: pro forma
0.67
0.91
0.97
Diluted: as reported
0.82
1.02
1.09
Diluted: pro forma
0.64
0.87
0.93
Because the SFAS No. 123 method of accounting has not been applied to options granted prior to January 1, 1995, the resulting pro forma compensation cost may not be representative of that to be expected in future years.
The weighted average fair value per share of options granted in 1999, 2000 and 2001 was $11.21, $11.01 and $11.21, respectively.
Page F-15
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for the grants in 1999, 2000 and 2001, respectively: no dividend yield for all years; expected volatility of 54% for 1999, 65% for 2000 and 48% for 2001; risk-free interest rates of 5.3%, 4.9% and 4.4% for 1999, 2000 and 2001, respectively; and expected lives of 4.6 years for 1999 and 2000 and 5.2 years for 2001. At December 31, 2001, the options outstanding have the following characteristics (in thousands, except per share amount):
__________OPTIONS OUTSTANDING__________
___OPTIONS EXERCISABLE__
WEIGHTED
WEIGHTED
AVERAGE
WEIGHTED
NUMBER
AVERAGE
REMAINING
NUMBER
AVERAGE
EXERCISE PRICE
OF
EXERCISE
CONTRACT
OF
EXERCISE
______RANGE______
__OPTIONS__
____PRICE___
____LIFE____
__OPTIONS__
____PRICE___
$ 5.31 - $ 9.88
543
$ 7.27
0.72
543
$ 7.27
11.38 - 17.75
2,166
16.23
5.87
1,249
16.01
19.25 - 22.69
1,384
21.83
7.44
423
20.43
22.75 - 46.00
1,192
25.71
7.64
402
26.00
(a) The 1991 Stock Option Plan
During 1991, the Board of Directors approved the 1991 Stock Option Plan which, as amended, provides for grants up to 6,475,000 incentive and nonqualified stock options at the discretion of the Compensation Committee of the Board of Directors. Incentive Stock Options are granted at the fair market value on the date of grant and expire ten years from the date of grant. Incentive Stock Options for greater than 10% shareholders are granted at 110% of the fair market value and expire five years from the date of grant. Nonqualified options may be granted at no less than 100% of the fair market value on the date of grant. The vesting schedule of all options is determined by the Compensation Committee of the Board of Directors at the time of grant.
(b) The 1991 Director Option Plan
During 1991, the Board of Directors approved the 1991 Director Option Plan (as amended, the "1991 Director Plan") pursuant to which Directors who were not officers or employees of the Company were eligible to receive nonstatutory options to purchase shares of the Company's Common Stock. The time period for granting options under the 1991 Director Plan expired in accordance with the terms of the plan in June 1996.
(c) The 1997 Director Option Plan
During 1997, the Board of Directors approved the 1997 Director Option Plan (the "1997 Director Plan") pursuant to which Directors who were not officers or employees of the Company received nonstatutory options to purchase shares of the Company's Common Stock. On May 19, 1999, this plan was terminated and replaced with the 1999 Director Stock Plan.
(d) 1998 Stock Incentive Plan
During 1998, the Board of Directors approved the 1998 Stock Incentive Plan (the "1998 Stock Plan") which provides for grants of incentive and nonqualified stock options at the discretion of the Compensation Committee of the Board of Directors. A total of 3,500,000 shares of Common Stock may be issued under the 1998 Stock Plan as amended. Options granted under the 1998 Stock Plan may not be granted at an exercise price less than the fair market value of the Common Stock on the date granted (or less than 110% of the fair market value in the case of incentive stock options granted to holders of more than 10% of the Company's Common Stock). Options may not be granted for a term of more than ten years. The vesting schedule of all options granted under the 1998 Stock Plan is determined by the Compensation Committee of the Board of Directors at the time of grant.
(e) The 1999 Director Stock Plan
During 1999, the Board of Directors approved the 1999 Director Stock Plan pursuant to which Directors who were not officers or employees of the Company received shares of the Company's Common Stock. A total of 80,000 shares of Common Stock were issuable under the 1999 Director Stock Plan. In May 2000, the 1999 Director Stock Plan was terminated and replaced with the 2000 Director Option Plan. As of December 31, 2000, 13,364 shares had been issued under the 1999 Director Stock Plan, and the fair value of these shares of $0.4 million was charged to expense in 1999 and 2000.
Page F-16
(f) The 2000 Director Option Plan
During 2000, the Board of Directors approved the 2000 Director Option Plan (the "2000 Director Plan") pursuant to which Directors who are not officers or employees of the Company receive nonstatutory options to purchase shares of the Company's Common Stock. Under the 2000 Director Plan each non-employee Director is granted an option to purchase 6,500 shares of Common Stock at each annual meeting of the Company's shareholders. Options granted under the 2000 Director Plan have an exercise price equal to the fair market value of the Company's Common Stock on the date of grant, vest fully on the first anniversary of the date of grant and expire ten years from the date of grant. A total of 200,000 shares of Common Stock may be issued under the plan.
A summary of the status of the Company's stock option plans as of December 31, 1999, 2000 and 2001 and changes during the years then ended is presented in the table and narrative below (in thousands, except weighted average exercise price):
________TOTAL________
______EXERCISABLE_____
WEIGHTED
WEIGHTED
NUMBER
AVERAGE
NUMBER
AVERAGE
OF
EXERCISE
OF
EXERCISE
SHARES
___PRICE__
__SHARES_
___PRICE__
Outstanding, December 31, 1998
5,379
$ 14.26
2,600
$ 11.17
Granted
1,341
$ 22.51
Exercised
(669)
7.35
Terminated
(325
)
18.45
Outstanding, December 31, 1999
5,726
$ 16.78
2,624
$ 13.85
Granted
1,189
19.20
Exercised
(601)
15.30
Terminated
(682
)
19.10
Outstanding, December 31, 2000
5,632
$ 17.17
2,815
$ 14.82
Granted
1,114
23.88
Exercised
(927)
13.86
Terminated
(534
)
19.58
Outstanding, December 31, 2001
5,285
$ 18.98
2,617
$ 16.45
=====
=======
(g) Employee Stock Purchase Plans
During 1994, the Board of Directors approved the 1994 Employee Stock Purchase Plan, under which the Company had reserved up to an aggregate of 300,000 shares of Common Stock for issuance in semiannual offerings over a three-year period. During 1997, the Board of Directors approved the 1997 Employee Stock Purchase Plan, under which the Company has reserved and may issue up to an aggregate of 420,000 shares of Common Stock in semiannual offerings. Also during 1997, the Board of Directors approved the 1997 International Employee Stock Purchase Plan, under which the Company has reserved and may issue up to an aggregate of 30,000 shares of Common Stock in semiannual offerings. Stock is sold under each of these plans at 85% of fair market value, as defined. Shares subscribed to and issued under the plans were 66,900 in 1999, 68,900 in 2000 and 54,550 in 2001.
Under SFAS No. 123, pro forma compensation cost is recognized for the fair value of the employees' purchase rights, which was estimated using the Black-Scholes model with the following assumptions for 1999, 2000 and 2001, respectively: no dividend yield for all years; an expected life of one year for all years; expected volatility of 54% for 1999, 65% for 2000 and 48% for 2001; and risk-free interest rates of 5.5%, 4.7% and 2.2% for 1999, 2000 and 2001, respectively. The weighted-average fair value of those purchase rights granted in 1999, 2000 and 2001 was $7.40, $6.27 and $7.07 per share, respectively.
(8) PREFERRED STOCK PURCHASE RIGHTS
On December 17, 1996, the Company adopted a Shareholder Rights Plan and declared a dividend of one preferred stock purchase right for each outstanding share of Common Stock to stockholders of record at the close of business on December 30, 1996. Under certain conditions, each right may be exercised to purchase one one-thousandth of a share of Series A Stock at a purchase price of $200.00. The rights will be exercisable only if a person or group has acquired beneficial ownership of 20% or more of the Common Stock or commenced a tender or exchange offer that would result in such a person or group owning 30% or more of the Common Stock. The Company generally will be entitled to redeem the rights, in whole, but not in part, at a price of $.01 per right at any time until the tenth business day following a public announcement that a 20% stock position has been acquired and in certain other circumstances.
Page F-17
If any person or group becomes a beneficial owner of 20% or more of the Common Stock (except pursuant to a tender or exchange offer for all shares at a fair price as determined by the outside members of the Company's Board of Directors), each right not owned by a 20% stockholder will enable its holder to purchase such number of shares of Common Stock as is equal to the exercise price of the right divided by one-half of the current market price of the Common Stock on the date of the occurrence of the event. In addition, if the Company thereafter is acquired in a merger or other business combination with another person or group in which it is not the surviving corporation or in connection with which its Common Stock is changed or converted, or if the Company sells or transfers 50% or more of its assets or earning power to another person, each right that has not previously been exercised will entitle its holder to purchase such number of shares of common stock of such other person as is equal to the exercise price of the right divided by one-half of the current market price of such common stock on the date of the occurrence of the event.
(9) IDEXX RETIREMENT AND INCENTIVE SAVINGS PLAN
The Company has established the IDEXX Retirement and Incentive Savings Plan (the "401(k) Plan"). Employees eligible to participate in the 401(k) Plan may contribute specified percentages of their salaries, a portion of which will be matched by the Company. In addition, the Company may make contributions to the 401(k) Plan at the discretion of the Board of Directors. There were no discretionary contributions in 1999, 2000 and 2001.
(10) SIGNIFICANT CUSTOMERS
During the year ended December 31, 1999, one customer accounted for 10% of the Company's revenue. The significant customer was a wholesale distributor of the Company's veterinary products. No customer accounted for greater than 10% of revenue in 2000 and 2001.
(11) SEGMENT REPORTING
The Company adopted the provisions of SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information" ("SFAS No. 131"), during the fourth quarter of 1998. SFAS No. 131 requires disclosures about operating segments in annual financial statements and requires selected information about operating segments in interim financial statements. It also requires related disclosures about products and services and geographic areas. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company's chief operating decision maker is the chief executive officer.
The Company is organized into business units by market and customer group. The Company's reportable operating segments include the Companion Animal Group ("CAG"), the Food and Environmental Division ("FED") and other. The CAG develops, designs, and distributes products and performs services for veterinarians. The CAG also manufactures certain biology-based test kits for veterinarians and develops products for therapeutic applications in companion animals. FED develops, designs, manufactures and distributes products and performs services to detect disease and contaminants in food animals, food, water and food processing facilities. In 1999 and 2000, the Company disposed of products and services for food microbiology testing. Both the CAG and FED distribute products and services world-wide. Other is primarily comprised of corporate research and development and interest income and includes cash, short-term investments, long-term investments, deferred assets and other miscellaneous current and long-term assets.
Page F-18
The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies except that most interest income and expense are not allocated to individual operating segments and income taxes are allocated pro rata to pretax income (loss). Below is the Company's segment information (in thousands):
___CAG__
__FED_
_OTHER_
_TOTAL_
Revenue
$ 308,048
$ 78,033
$ --
$ 386,081
Depreciation and amortization
20,389
1,840
--
22,229
Interest income
--
--
2,229
2,229
Provision for income taxes
13,176
8,163
(178)
21,161
Net income (loss)
23,423
14,513
(316)
37,620
Segment assets
207,515
41,270
124,322
373,107
Expenditures for property
16,749
632
--
17,381
Revenue
$ 295,740
$ 71,692
$ --
$ 367,432
Depreciation and amortization
16,855
2,626
--
19,481
Interest income
87
18
4,891
4,996
Provision for income taxes
13,469
7,117
1,029
21,615
Net income
22,825
12,062
1,745
36,632
Segment assets
191,147
44,364
100,285
335,796
Expenditures for property
14,215
1,305
--
15,520
Revenue
$ 279,426
$ 78,944
$ --
$ 358,370
Depreciation and amortization
14,289
2,920
--
17,209
Interest income (expense)
(151)
--
5,879
5,728
Provision for income taxes
14,182
4,108
1,677
19,967
Net income
23,140
6,704
2,734
32,578
Segment assets
156,657
36,632
164,693
357,982
Expenditures for property
6,051
2,241
--
8,292
2001
2000
1999
Revenue by principal geographic area based on the location of the customer was as follows (in thousands):
________YEARS ENDED DECEMBER 31,________
_____1999____
_____2000____
_____2001____
Americas
United States
$ 263,015
$ 269,782
$ 279,702
Canada
9,775
10,449
11,352
South America
6,723
4,935
5,456
Europe
United Kingdom
23,437
24,612
28,005
Germany
9,019
7,784
8,372
France
8,082
7,605
7,600
Other Europe
16,416
16,359
17,113
Asia Pacific Region
Japan
11,629
12,902
12,812
Australia
5,859
6,945
8,776
Other Asia Pacific
4,415
6,059
6,893
Total
$ 358,370
$ 367,432
$ 386,081
========
========
========
Page F-19
Net long-lived assets by principal geographic areas was as follows (in thousands):
___________DECEMBER 31,__________
___1999___
___2000___
___2001___
Americas
United States
$ 81,258
$ 80,721
$ 80,036
Other Americas
514
177
161
Europe
United Kingdom
1,452
18,299
16,660
Germany
137
121
66
France
73
76
52
Netherlands
1,631
1,374
1,252
Other Europe
519
375
297
Asia Pacific Region
Japan
1,178
874
841
Australia
1,420
4,880
4,483
Other Asia Pacific
661
725
575
Total
$ 88,843
$ 107,622
$ 104,423
========
========
========
(12) ACCRUED EXPENSES
Accrued expenses consist of the following (in thousands):
_____DECEMBER 31,____
___2000___
___2001___
Accrued compensation and related expenses
$ 12,910
$ 13,798
Accrued income taxes
9,963
9,213
Other accrued expenses
17,035
15,879
$ 39,908
$ 38,890
========
========
(13) ACQUISITIONS
(a) Veterinary Reference Laboratories
The Company's consolidated results of operations include the results of operations of two veterinary reference laboratory businesses acquired in 1999 for an aggregate purchase price of $4.1 million, the issuance of $0.5 million in unsecured notes payable, plus the assumption of certain liabilities. The Company's consolidated results of operations include two veterinary reference laboratory businesses acquired in 2000 for an aggregate purchase price of $3.4 million plus the assumption of certain liabilities.
In connection with these acquisitions, the company entered into non-competition agreements with the sellers for up to ten years. The Company has accounted for these acquisitions under the purchase method of accounting. The results of operations of each of these businesses has been included in the Company's consolidated results of operations since their respective dates of acquisition. The Company has not presented pro forma information because of immateriality. These acquisitions are as follows:
* On March 31, 1999, the Company, through its wholly-owned subsidiary, IDEXX Veterinary Services, Inc., acquired the assets and assumed certain liabilities of the veterinary laboratory business of Sonora Quest Laboratories, LLC ("Sonora"), which operated a veterinary laboratory in Arizona.
* On December 1, 1999, the Company, through its wholly-owned subsidiary, IDEXX Veterinary Services, Inc., acquired the assets and assumed certain liabilities of the veterinary laboratory business of the Tufts University School of Veterinary Medicine, which operated a veterinary laboratory in Massachusetts.
* On March 9, 2000, the Company, through its wholly-owned subsidiary, IDEXX Veterinary Services, Inc., acquired the assets and certain liabilities of Sierra Veterinary Laboratory LLC ("Sierra"), based in Los Angeles, California. In addition, the Company agreed to make future payments in each of the next four years based on the results of operations of Sierra, which will be treated as additional purchase price.
Page F-20
* On July 1, 2000, the Company, through its wholly-owned subsidiary, IDEXX Laboratories Pty. Ltd., acquired Veterinary Pathology Services Pty. Ltd., a veterinary laboratory business with locations in Adelaide, Brisbane and Sydney, Australia.
(b) Genera Technologies Limited
On August 11, 2000, the Company acquired Genera Technologies Limited, a U.K. based provider of products that test for cryptosporidia in water, for $8.9 million in cash and $8.3 million in notes to the former principal shareholder, of which $7.0 million is secured by cash in escrow. The Company also agreed to make four annual additional payments of up to $0.6 million (totaling $2.5 million) based upon performance of the business after the acquisition. The Company was not required to make the first annual payment. The Company has accounted for this acquisition under the purchase method of accounting and has included the results of operations in its consolidated results since the acquisition date. The Company has not presented pro forma information because of immateriality.
(c) Blue Ridge Pharmaceuticals, Inc.
On October 1, 1998, the Company acquired all of the capital stock of Blue Ridge Pharmaceuticals, Inc. ("Blue Ridge") for approximately $39.1 million in cash, $7.8 million in notes, 115,000 shares of the Company's Common Stock and warrants to acquire 806,000 shares of Common Stock at $31.59 per share which expire on December 31, 2003. In addition, the Company agreed to issue up to 1,241,000 shares of its Common Stock based on the achievement by the Company's pharmaceutical business (including Blue Ridge) of net sales and operating profit targets through 2004. All former shareholders received equal value in the form of cash/notes/stock, warrants and contingent shares on a per share basis. The notes bore interest at 6% annually and were paid in two equal annual installments on October 1, 1999 and 2000 to certain key employees of Blue Ridge. The 115,000 shares of Common Stock were issued in 2001 to a key employee of Blue Ridge. Blue Ridge is a development-stage animal health pharmaceutical company located in Greensboro, North Carolina. The Company has accounted for this acquisition under the purchase method of accounting and has included the results of operations in its consolidated results since the date of acquisition. The Company will record the issuance of any of the 1,241,000 shares discussed above as additional goodwill when the shares are issued.
(14) DIVESTITURES
Through a series of transactions in December 1999 and February 2000, the Company sold certain assets and subsidiaries of its Food and Environmental Division. As a result of these transactions, the Company recorded a net loss of approximately $0.4 million in 1999 and a net gain of $1.5 million in 2000. The results of operations of these businesses have been included in the consolidated results of operations through the respective sale dates. Pro forma information has not been presented because of immateriality.
(a) IDEXX Food Safety Net Services, Inc.
On December 21, 1999, the Company sold substantially all the assets in the business of IDEXX Food Safety Net Services, Inc. to Food Safety Net Services, Ltd. for $0.4 million cash, a $0.2 million note payable and the assumption of certain liabilities. The note bears interest at 6% and is due in twelve quarterly installments. In addition, the Company entered into a non-compete agreement for five years.
(b) Food Products and Acumedia Manufacturers, Inc.
During February 2000, the Company sold certain assets and the rights to its Lightning â , Simplate â and Bind â product lines and its subsidiary Acumedia for $10.4 million in cash, a $0.5 million note payable, and the assumption of certain liabilities. The note bore interest at 7% and was paid in 2001. In addition, the Company entered into non-compete agreements for up to five years.
(15) SERVICE REVENUE
Service revenue, which includes laboratory service revenue and maintenance and repair revenue, totaled approximately $72.6 million, $86.9 million and $96.1 million in 1999, 2000 and 2001, respectively. The cost of service revenue in 1999, 2000 and 2001 totaled approximately $58.8 million, $71.0 million and $74.1 million, respectively.
Page F-21
(16) STOCK REPURCHASE PROGRAM
During 1999 and 2000, the Board of Directors authorized the purchase of up to an aggregate of ten million shares of the Company's Common Stock in the open market or in negotiated transactions. As of December 31, 2000 and 2001, approximately 7,024,000 shares and 7,614,000 shares, respectively, of Common Stock had been repurchased under this program.
(17) SUBSEQUENT EVENT
In January 2002, the Company's Founder, Chairman and Chief Executive Officer was succeeded by its current Chairman and Chief Executive Officer. As a result of an October 2001 employment agreement, the Company is required to make certain payments to its former Chief Executive Officer and provide certain benefits to him following a succession to a new Chief Executive Officer. As a result of the succession, the Company will incur a pre-tax charge in the first quarter of 2002 of approximately $3.0 million, $2.0 million of which is non-cash.
(18) SUMMARY OF QUARTERLY DATA (UNAUDITED)
A summary of quarterly data follows (in thousands, except per share data):
|
___________________2000 QUARTER ENDED___________________ |
|||
|
MARCH 31 |
__JUNE 30__ |
SEPTEMBER 30 |
DECEMBER 31 |
Revenue |
$ 91,389 |
$ 94,076 |
$ 90,902 |
$ 91,065 |
Gross profit |
43,782 |
46,419 |
42,957 |
44,018 |
Operating income |
11,508 |
13,879 |
13,514 |
14,350 |
Net income |
8,034 |
9,528 |
9,269 |
9,801 |
Earnings per share: |
||||
Basic |
0.23 |
0.27 |
0.27 |
0.29 |
Diluted |
0.22 |
0.26 |
0.26 |
0.28 |
___________________2001 QUARTER ENDED___________________ |
||||
|
MARCH 31 |
__JUNE 30__ |
SEPTEMBER 30 |
DECEMBER 31 |
Revenue |
$ 91,426 |
$ 102,001 |
$ 97,522 |
$ 95,132 |
Gross profit |
43,865 |
49,513 |
46,421 |
43,532 |
Operating income |
11,188 |
15,048 |
15,447 |
14,869 |
Net income |
7,609 |
9,966 |
10,217 |
9,828 |
Earnings per share: |
||||
Basic |
0.23 |
0.30 |
0.31 |
0.29 |
Diluted |
0.22 |
0.29 |
0.30 |
0.28 |
Page F-22
SCHEDULE II
IDEXX LABORATORIES, INC. AND SUBSIDIARIES |
VALUATION AND QUALIFYING ACCOUNTS |
(in thousands) |
BALANCE AT |
CHARGED TO |
BALANCE |
||
BEGINNING |
COSTS AND |
AT END |
||
__OF YEAR___ |
__EXPENSES__ |
WRITE-OFFS |
OF YEAR |
|
Allowance for doubtful accounts receivable: |
||||
December 31, 1999 |
5,368 |
270 |
810 |
4,828 |
December 31, 2000 |
4,828 |
647 |
1,085 |
4,390 |
December 31, 2001 |
4,390 |
547 |
944 |
3,993 |
Accrued severance and lease cancellation reserve: |
||||
December 31, 1999 |
3,225 |
-- |
2,572 |
653 |
December 31, 2000 |
653 |
2,056 |
805 |
1,904 |
December 31, 2001 |
1,904 |
2,248 |
3,850 |
302 |
Page F-23
EXHIBIT 10.2
IDEXX LABORATORIES, INC. |
1991 STOCK OPTION PLAN |
(as of February 13, 2002) |
1. Purpose .
The purpose of this plan (the "Plan") is to secure for IDEXX Laboratories, Inc. (the "Company") and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations who are expected to contribute to the Company's future growth and success. Except where the context otherwise requires, the term "Company" shall include the parent and all present and future subsidiaries of the Company as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the "Code"). Those provisions of the Plan which make express reference to Section 422 of the Code shall apply only to Incentive Stock Options (as that term is defined in the Plan).
2. Type of Options and Administration .
(a) Types of Options . Options granted pursuant to the Plan shall be authorized by action of the Board of Directors of the Company (or a Committee designated by the Board of Directors) and may be either incentive stock options ("Incentive Stock Options") meeting the requirements of Section 422 of the Code or non-qualified options which are not intended to meet the requirements of Section 422 of the Code.
(b) Administration . The Plan will be administered by the Board of Directors of the Company, whose construction and interpretation on the terms and provisions of the Plan shall be final and conclusive. The Board of Directors may in its sole discretion grant options to purchase shares of the Company's Common Stock, par value $.10 per share ("Common Stock"), and issue shares upon exercise of such options as provided in the Plan. The Board shall have authority, subject to the express provisions of the Plan, to construe the respective option agreements and the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan, to determine the terms and provisions of the respective options agreements, which need not be identical, and to make all other determinations in the judgment of the Board of Directors necessary or desirable for the administration of the Plan. The Board of Directors may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any option agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Board of Directors shall be liable for any action or determination made in good faith. The Board of Directors may, to the full extent permitted by or consistent with applicable laws or regulations (including, without limitation, applicable state law and Rule 16b-3 promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), or any successor rule ("Rule 16b-3")), delegate any or all of its powers under the Plan to a committee (the "Committee") appointed by the Board of Directors, and if the Committee is so appointed all references to the Board of Directors in the Plan shall mean and relate to such Committee or to the executive officers referred to in Section 2(c) to the extent that the Board of Directors' power or authority under the Plan has been delegated to such executive officers.
(c) Delegation to Executive Officers . To the extent permitted by applicable law, the Board of Directors may delegate to one or more executive officers of the Company the power to grant options to employees or officers of the Company or any of its present or future subsidiary corporations and to exercise such other powers under the Plan as the Board of Directors may determine, provided that the Board of Directors shall fix the terms of the options to be granted by such executive officers (including the exercise price of such options, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to options that the executive officers may grant; provided further, however, that no executive officer shall be authorized to grant options to any "executive officer" of the Company (as defined by Rule 3b-7 under the Exchange Act) or to any "officer" of the Company (as defined by Rule 16a-1 under the Exchange Act).
Page 1
(d) Applicability of Rule 16b-3 . Those provisions of the Plan which make express reference to Rule 16b-3 shall apply to the Company only at such time as the Company's Common Stock or another class of equity security is registered under the Exchange Act, and then only to such persons as are required to file reports under Section 16(a) of the Exchange Act.
3. Eligibility .
(a) General . Options may be granted to persons who are, at the time of grant, employees or officers of the Company; provided , that Incentive Stock Options may be granted only to persons who are eligible to receive such options under Section 422 of the Code. In additional, no person shall be granted any Incentive Stock Option under the Plan who, at the time such option is granted, owns, directly or indirectly, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, unless the requirements of Section 11(b) are satisfied. The attribution of stock ownership provisions of Section 424(d) of the Code, and any successor provisions thereto, shall be applied in determining the shares of stock owned by a person for purposes of applying the foregoing percentage limitation. A person who has been granted an option may, if he or she is otherwise eligible, be granted an additional option or options if the Board of Directors shall so determine. Subject to adjustment as provided in Section 15 below, the maximum number of shares with respect to which options may be granted to any employee under the Plan shall not exceed 1,000,000 shares of common stock during any one calendar year. For the purpose of calculating such maximum number, (a) an option shall continue to be treated as outstanding notwithstanding its repricing, cancellation, or expiration and (b) the repricing of an outstanding option or the issuance of a new option in substitution for a cancelled option shall be deemed to constitute the grant of a new additional option separate from the original grant of the option that is repriced or cancelled.
(b) Grant of Options to Directors and Officers . From and after the registration of the Common Stock of the Company under the Exchange Act, the selection of a director or an officer (as the terms "director" and "officer" are defined for the purposes of Rule 16b-3) as a recipient of an option, the timing of the option grant, the exercise price of the option and the number of shares subject to the option shall be determined either (i) by the Board of Directors, of which all members shall be "disinterested persons" (as hereinafter defined), or (ii) by a committee of two or more directors having full authority to act in the matter, of which all members shall be "disinterested persons". For the purposes of the Plan, a director shall be deemed to be a "disinterested person" only is such person qualifies as a "disinterested person" within the meaning of Rule 16b-3, as such term is interpreted from time to time.
Page 2
4. Stock Subject to Plan .
Subject to adjustment as provided in Section 15 below, the maximum number of shares of Common Stock of the Company which may be issued and sold under the Plan is 6,475,000 shares. Such shares may be authorized and unissued shares or may be shares issued and thereafter acquired by the Company. If an option granted under the Plan shall expire or terminate for any reason without having been exercised in full, the unpurchased shares subject to such option shall again be available for subsequent option grants under the Plan. If shares issued upon exercise of an option under the Plan are tendered to the Company in payment of the exercise price of an option granted under the Plan, such tendered shares shall again be available for subsequent option grants under the Plan; provided, that in no event shall (i) the total number of shares issued pursuant to the exercise of Incentive Stock Options under the Plan, on a cumulative basis, exceed the maximum number of shares authorized for issuance under the Plan exclusive of shares made available for issuance pursuant to this sentence or (ii) the total number of shares issued pursuant to the exercise of options by persons who are required to file reports under Section 16(a) of the Exchange Act, on a cumulative basis, exceed the maximum number of shares authorized for issuance under the Plan exclusive of shares made available for issuance pursuant to this sentence.
5. Forms of Option Agreements .
As a condition to the grant of an option under the Plan, each recipient of an option shall execute an option agreement in such form not inconsistent with the Plan as may be approved by the Board of Directors. Each option agreement shall specifically state whether the options granted thereby are intended to be Incentive Stock Options or non-qualified options. Such option agreements may differ among recipients.
6. Purchase Price .
(a) General . The purchase price per share of stock deliverable upon the exercise of an option shall be determined by the Board of Directors, provided , however , that the exercise price shall not be less than 100% of the fair market value of such stock, as determined by the Board of Directors, at the time of grant of such option, or less than 110% of such fair market value in the case of options described in Section 11(b).
(b) Payment of Purchase Price . Options granted under the Plan may provide for the payment of the exercise price by delivery of cash or a check to the order of the Company in an amount equal to the exercise price of such options, or, to the extent provided in the applicable option agreement, (i) by delivery to the Company of shares of Common Stock of the Company already owned by the optionee having a fair market value equal in amount to the exercise price of the options being exercised, (ii) by any other means which the Board of Directors determines are consistent with the purpose of the Plan and with the applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 and Regulation T promulgated by the Federal Reserve Board) or (iii) by any combination of such methods of payment. The fair market value of any shares of the Company's Common Stock or other non-cash consideration which may be delivered upon exercise of an option shall be determined by the Board of Directors.
Page 3
7. Option Period .
Each option and all rights thereunder shall expire on such date as the Board of Directors shall determine, except that (i) in the case of an Incentive Stock Option, such date shall not be later than ten years after the date on which the option is granted, (ii) in the case of an Incentive Stock Option described in Section 11(b), such date shall not be later than five years after the date on which the option is granted and (iii) in all cases, options shall be subject to earlier termination as provided in the Plan.
8. Exercise of Options .
Each option granted under the Plan shall be exercisable either in full or in installments at such time or times and during such period as shall be set forth in the agreement evidencing such option, subject to the provisions of the Plan.
9. Nontransferability of Options .
Incentive Stock Options shall not be assignable or transferable by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of decent and distribution, and, during the life of the optionee, shall be exercisable only by the optionee. With the approval of the Board of Directors, non-qualified stock options may be transferred by gift to (i) one or more members of the optionee's family or entities controlled by, or for the benefit of the optionee or such family members, or (ii) one or more charitable organizations (including charitable trusts). Except as the Board of Directors may otherwise determine, no option or interest therein may be transferred, assigned, pledged or hypothecated by the optionee during his lifetime, whether by operation of law or otherwise, or be made subject to execution, attachment or similar process.
10. Effect of Termination of Employment
Except as provided in Section 11(d) with respect to Incentive Stock Options, the Board of Directors shall determine the period of time during which an optionee may exercise an option following (i) the termination of the optionee's employment with the Company or (ii) the death or disability of the optionee. Such periods shall be set forth in the agreement evidencing such option.
11. Incentive Stock Options .
Options granted under the Plan which are intended to be Incentive Stock Options shall be subject to the following additional terms and conditions:
Page 4
(a) Express Designation . All Incentive Stock Options granted under the Plan shall, at the time of grant, be specifically designated as such in the option agreement covering such Incentive Stock Options.
(b) 10% Stockholder . If any employee to whom an Incentive Stock Option is to be granted under the Plan is, at the time of the grant of such option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership rules of Section 424(d) of the Code), then the following special provisions shall be applicable to the Incentive Stock Option granted to such individual:
(i) the purchase price per share of the Common Stock subject to such Incentive Stock Option shall not be less than 110% of the fair market value of one share of Common Stock at the time of grant; and
(ii) the option exercise period shall not exceed five years from the date of grant.
(c) Dollar Limitation . For so long as the Code shall so provide, options granted to any employee under the Plan (and any other incentive stock option plans of the Company) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such options, in the aggregate, become exercisable for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date or dates of grant) of more than $100,000.
(d) Termination of Employment, Death or Disability . No Incentive Stock Option may be exercised unless, at the time of such exercise, the optionee is, and has been continuously since the date of grant of his or her option, employed by the Company, except that:
(i) an Incentive Stock Option may be exercised within the period of three months after the date the optionee ceases to be an employee of the Company (or within such lesser period as may be specified in the applicable option agreement), provided, that the agreement with respect to such option may designate a longer exercise period and that the exercise after such three-month period shall be treated as the exercise of a non-qualified option under the Plan;
(ii) if the optionee dies while in the employ of the Company, or within three months after the optionee ceases to be such an employee, the Incentive Stock Option may be exercised by the person to whom it is transferred by will or the laws of descent and distribution within the period of one year after the date of death (or within such lesser period as may be specified in the applicable option agreement); and
(iii) if the optionee becomes disabled (within the meaning of Section 22(e)(3) of the Code or any successor provision thereto) while in the employ of the Company, the Incentive Stock Option may be exercised within the period of one year after the date the optionee ceases to be such an employee because of such disability (or within such lesser period as may be specified in the applicable option agreement).
Page 5
For all purposes of the Plan and any option granted hereunder, "employment" shall be defined in accordance with the provisions of Section 1.421-7(h) of the Income Tax Regulations (or any successor regulations). Notwithstanding the foregoing provisions, no Incentive Stock Option may be exercised after its expiration date.
12. Additional Provisions .
(a) Additional Option Provisions . The Board of Directors may, in its sole discretion, include additional provision in any option agreement covering options granted under the Plan, including without limitation restrictions on transfer, repurchase rights, commitments to pay cash bonuses, to make, arrange for or guaranty loans or to transfer other property to optionees upon exercise of options, or such other provisions as shall be determined by the Board of Directors; provided that such additional provisions shall not be inconsistent with any other term or condition of the Plan and such additional provisions shall not cause any Incentive Stock Option granted under the Plan to fail to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code.
(b) Acceleration, Extension, Etc . The Board of Directors may, in its sole discretion, (i) accelerate the date or dates on which all or any particular option or options granted under the Plan may be exercised or (ii) extend the dates during which all, or any particular option or options granted under the Plan may be exercised; provided, however, that no such extension shall be permitted if it would cause the Plan to fail to comply with Section 422 of the Code or with Rule 16b-3.
13. General Restrictions .
(a) Investment Representations . The Company may require any person to whom an option is granted, as a condition of exercising such option, to give written assurances in substance and form satisfactory to the Company to the effect that such person is acquiring the Common Stock subject to the option for his or her own account for investment and not with any present intention of selling or otherwise distributing the same, and to such other effects as the Company deems necessary or appropriate in order to comply with federal and applicable state securities laws, or with covenants or representations made by the Company in connection with any public offering of its Common Stock.
(b) Compliance With Securities Laws . Each option shall be subject to the requirement that if, at any time, counsel to the Company shall determine that the listing, registration or qualification of the shares subject to such option upon any securities exchange or under any state or federal law, or the consent or approval of any governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of shares thereunder, such option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, or satisfaction of such condition shall have been effected or obtained on conditions acceptable to the Board of Directors. Nothing herein shall be deemed to require the Company to apply for or to obtain such listing, registration or qualification, or to satisfy such condition.
14. Rights as a Shareholder .
The holder of an option shall have no rights as a shareholder with respect to any shares covered by the option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares) until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued.
Page 6
15. Adjustment Provisions for Recapitalizations and Related Transactions .
(a) General . If, through or as a result of any merger, consolidation, sale of all or substantially all of the assets of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other similar transaction, (i) the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock or other securities, an appropriate and proportionate adjustment may be made in (x) the maximum number and kind of shares reserved for issuance under the Plan, (y) the number and kind of shares or other securities subject to then outstanding options under the Plan, and (z) the price for each share subject to any then outstanding options under the Plan, without changing the aggregate purchase price as to which such options remain exercisable, provided that no adjustment shall be made pursuant to this Section 15 if such adjustment would cause the Plan to fail to comply with Section 422 of the Code or with Rule 16b-3.
(b) Board Authority to Make Adjustments . Any adjustments under this Section 15 will be made by the Board of Directors, whose determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments.
16. Merger, Consolidation, Asset Sale, Liquidation, Etc .
(a) General. In the event of a consolidation or merger or sale of all or substantially all of the assets of the Company in which outstanding shares of Common Stock are exchanged for securities, cash or other property of any other corporation or business entity or in the event of a liquidation of the Company (each of these events collectively being referred to herein as an "Acquisition Event"), the Board shall provide that all outstanding options shall be assumed, or equivalent options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), provided that any options substituted for Incentive Stock Options shall satisfy, in the determination of the Board, the requirements of Section 424(a) of the Code. Notwithstanding the foregoing, if the acquiring or succeeding corporation (or an affiliate thereof) does not agree to assume, or substitute for, such options, then the Board of Directors shall upon written notice to the optionees, provide that all then unexercised options will become exercisable in full as of a specified time (the "Acceleration Time") prior to an Acquisition Event and will terminate immediately prior to the consummation of such Acquisition Event, except to the extent exercised by the optionees before the consummation of such Acquisition Event; provided, however, that, in the event of an Acquisition Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share of Common Stock surrendered pursuant to such Acquisition Event (the "Acquisition Price"), then the Board may instead provide that all outstanding options shall terminate upon consummation of such Acquisition Event and that each optionee shall receive, in exchange therefor, a cash payment equal to the amount (if any) by which (A) the Acquisition Price multiplied by the number of shares of Common Stock subject to such outstanding options (whether or not then exercisable), exceeds (B) the aggregate exercise price of such options.
Page 7
(b) Substitute Options . The Company may grant options under the Plan in substitution for options held by employees of another corporation who become employees of the Company, or a subsidiary of the Company, as the result of a merger or consolidation of the employing corporation with the Company or a subsidiary of the Company, or as a result of the acquisition by the Company, or one of its subsidiaries, of property or stock of the employing corporation. The Company may direct that substitute options be granted on such terms and conditions as the Board of Directors considers appropriate in the circumstances.
(c) Acceleration of Options Upon Change of Control . Immediately prior to the consummation of a Change of Control, each then outstanding option under the Plan shall become immediately exercisable as to twenty-five percent (25%) of the number of shares as to which such option would otherwise not then be exercisable (rounded down to the nearest whole share), and the number of shares as to which each such option shall become exercisable on each vesting date set forth in the applicable option agreement shall be reduced by 25%. In addition, all such options held by an optionee that are not terminated pursuant to Section 16(a) above shall immediately become exercisable in full if and when, within 24 months after a Change of Control, such optionee's employment with the Company (or the acquiring or succeeding entity) is involuntarily terminated by the Company (or such acquiring or succeeding entity) other than for Cause (as defined below).
(d) Definition of Change of Control . "Change of Control" shall mean:
(i) The acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of either (A) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (d)(i), the following acquisitions shall not constitute a Change of Control: (1) any acquisition directly from the Company, (2) any acquisition by the Company, (3) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (4) any acquisition by any corporation pursuant to a transaction which satisfies the criteria set forth in clauses (A), (B) and (C) of subsection (d)(iii) of this Section 16; or
(ii) Individuals who, as of the date hereof, constitute the Board of Directors (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board of Directors; provided, however, that any individual becoming a director subsequently to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board of Directors; or
(iii) Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Business Combination"), in each case, unless, immediately following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of, respectively, the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, of the corporation resulting from such Business Combination (which as used in this Section 16(d)(iii) shall include, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination, or the combined voting power of the then-outstanding voting securities of such corporation and (C) at least half of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination; or
Page 8
(iv) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.
(e) Definition of Cause . "Cause" shall mean:
(i) the failure of the optionee to perform substantially the optionee's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness), which failure is not cured within 30 days after a written demand for substantial performance is delivered to the optionee by the optionee's manager or the Board of Directors which specifically identifies the manner in which such manager or the Board of Directors, as applicable, believes that the optionee has not substantially performed the optionee's duties, or
(ii) the engaging by the optionee in illegal conduct or gross misconduct which is injurious to the Company."
17. No Special Employment Rights .
Nothing contained in the Plan or in any option shall confer upon any optionee any right with respect to the continuation of his or her employment by the Company or interfere in any way with the right of the Company at any time to terminate such employment or to increase or decrease the compensation of the optionee.
Page 9
18. Other Employee Benefits .
Except as to plans which by their terms include such amounts as compensation, the amount of any compensation deemed to be received by an employee as a result of the exercise of an option or the sale of shares received upon such exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation, benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Board of Directors.
19. Amendment of the Plan .
(a) The Board of Directors may at any time, and from time to time, modify or amend the Plan in any respect, except that if at any time the approval of the shareholders of the Company is required under Section 422 of the Code or any successor provision with respect to Incentive Stock Options or under Rule 16b-3 or with respect to options held by persons who are required to file reports pursuant to Section 16(a) of the Exchange Act, the Board of Directors may not effect such modification or amendment without such approval. In addition, the Board of Directors may not amend Section 24 of the Plan without the prior approval of the shareholders of the Company.
(b) The termination or any modification or amendment of the Plan shall not, without the consent of an optionee, affect his or her rights under an option previously granted to him or her. With the consent of the optionee affected, the Board of Directors may amend outstanding option agreements in a manner not inconsistent with the Plan. The Board of Directors shall have the right to amend or modify (i) the terms and provisions of the Plan and of any outstanding Incentive Stock Options granted under the Plan to the extent necessary to qualify any or all such options for such favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code and (ii) the terms and provisions of the Plan and of any outstanding option to the extent necessary to ensure the qualification of the Plan under Rule 16b-3.
20. Withholding .
(a) The Company shall have the right to deduct from payments of any kind otherwise due to the optionee any federal, state or local taxes of any kind required by law to be withheld with respect to any shares issued upon exercise of options under the Plan. Subject to the prior approval of the Company, which may be withheld by the Company in its sole discretion, the optionee may elect to satisfy such obligations, in whole or in part, (i) by causing the Company to withhold shares of Common Stock otherwise issuable pursuant to the exercise of an option or (ii) by delivering to the Company shares of Common Stock already owned by the optionee. The shares so delivered or withheld shall have a fair market value equal to such withholding obligation. The fair market value of the shares used to satisfy such withholding obligation shall be determined by the Company as of the date that the amount of tax to be withheld is to be determined. An optionee who has made an election pursuant to this Section 20(a) may only satisfy his or her withholding obligation with shares of Common Stock which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.
Page 10
(b) Notwithstanding the foregoing, in the case of a director or officer, no election to use shares for the payment of withholding taxes shall be effective unless made in compliance with any applicable requirements of Rule 16b-3.
21. Cancellation and New Grant of Options, Etc .
The Board of Directors shall have the authority to effect, at any time and from time to time, with the consent of the affected optionees, (i) the cancellation of any or all outstanding options under the Plan and the grant in substitution therefor of new options under the Plan covering the same or different numbers of shares of Common Stock and having an option exercise price per share which may be lower or higher than the exercise price per share of the cancelled options or (ii) the amendment of the terms of any and all outstanding options under the Plan to provide an option exercise price per share which is higher or lower that the then-current exercise price per share of such outstanding options.
22. Effective Date and Duration of the Plan .
(a) Effective Date . The Plan shall become effective when adopted by the Board of Directors, but no Incentive Stock Option granted under the Plan shall become exercisable unless and until the Plan shall have been approved by the Company's shareholders. If such shareholder approval is not obtained within twelve months after the date of the Board's adoption of the Plan, no options previously granted under the Plan shall be deemed to be Incentive Stock Options and no further Incentive Stock Options shall be granted. Amendments to the Plan not requiring shareholder approval shall become effective when adopted by the Board of Directors; amendments requiring shareholder approval (as provided in Section 19) shall become effective when adopted by the Board of Directors, but no Incentive Stock Option granted after the date of such amendment shall become exercisable (to the extent that such amendment to the Plan was required to enable the Company to grant such Incentive Stock Option to a particular optionee) unless and until such amendment shall have been approved by the Company's shareholders. If such shareholder approval is not obtained within twelve months of the Board's adoption of such amendment, any Incentive Stock Options granted on or after the date of such amendment shall terminate to the extent that such amendment to the Plan was required to enable the Company to grant such option to a particular optionee. Subject to this limitation, options may be granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan.
(b) Termination . Unless sooner terminated in accordance with Section 16, the Plan shall terminate, with respect to Incentive Stock Options, upon the earlier of (i) the close of business on the day next preceding the tenth anniversary of the date of its adoption by the Board of Directors, or (ii) the date on which all shares available for issuance under the Plan shall have been issued pursuant to the exercise or cancellation of options granted under the Plan. Unless sooner terminated in accordance with Section 16, the Plan shall terminate with respect to options which are not Incentive Stock Options on the date specified in (ii) above. If the date of termination is determined under (i) above, then options outstanding on such date shall continue to have force and effect in accordance with the provisions of the instruments evidencing such options.
Page 11
23. Provisions for Foreign Participants .
The Board of Directors may, without amending the Plan, modify awards or options granted to participants who are foreign nationals or employed outside the United States to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.
24. Prohibition on Repricing of Options .
Neither the Board of Directors nor the Company may amend the terms of any issued and outstanding option to reduce the exercise price, other than pursuant to Section 15 of the Plan, without prior approval of shareholders of the Company.
Adopted by the Board of Directors on April 24, 1991; adopted by stockholders on June 10, 1991. |
Amended by the Board of Directors on February 12, 1992; amendment approved by stockholders |
on May 1, 1992. |
Amended by the Board of Directors on February 26, 1993; amendment approved by stockholders |
on May 18, 1993. |
Number of shares covered by the Plan reflects 2 for 1 stock split in the form of a stock dividend |
paid on October 1, 1993. |
Amended by the Board of Directors on February 9, 1995; amendment approved by stockholders |
on May 26, 1995. |
Number of shares covered by the Plan reflects 2 for 1 stock split in the form of a stock dividend |
paid on June 5, 1995. |
Amended by the Board of Directors on March 5, 1996; amendment approved by the stockholders |
on May 24, 1996. |
Amended by the Board of Directors on February 17, 1999. |
Amended by the Board of Directors on July 21, 1999. |
Amended by the Board of Directors on May 23, 2001. |
Amended by the Board of Directors on February 13, 2002. |
Page 12
EXHIBIT 10.10
IDEXX LABORATORIES, INC. |
1998 STOCK INCENTIVE PLAN |
(as of February 13, 2002) |
1. Purpose
The purpose of this 1998 Stock Incentive Plan (the "Plan") of IDEXX Laboratories, Inc., a Delaware corporation (the "Company"), is to advance the interests of the Company's stockholders by enhancing the Company's ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and performance-based incentives and thereby better aligning the interests of such persons with those of the Company's stockholders. Except where the context otherwise requires, the term "Company" shall include any present or future subsidiary corporations of IDEXX Laboratories, Inc. as defined in Section 424(f) of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the "Code").
2. Eligibility
All of the Company's employees, officers and directors (and any individuals who have accepted an offer for employment) are eligible to be granted options ("Options") to purchase shares of the Company's common stock, $.10 par value per share ("Common Stock"), under the Plan. Each person who has been granted an Option under the Plan shall be deemed a "Participant".
3. Administration, Delegation
(a) Administration by Board of Directors . The Plan will be administered by the Board of Directors of the Company (the "Board"). The Board shall have authority to grant Options and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Option in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board's sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Option. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith.
(b) Appointment of Committees . To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a "Committee"). All references in the Plan to the "Board" shall mean the Board or a Committee of the Board or the executive officers referred to in Section 3(c) to the extent that the Board's powers or authority under the Plan have been delegated to such Committee or executive officers.
Page 1
(c) Delegation to Executive Officers . To the extent permitted by applicable law, the Board may delegate to one or more executive officers of the Company the power to grant Options to employees or officers of the Company or any of its present or future subsidiary corporations and to exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the terms of the Options to be granted by such executive officers (including the exercise price of such Options, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to Options that the executive officers may grant; provided further, however, that no executive officer shall be authorized to grant Options to any "executive officer" of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) or to any "officer" of the Company (as defined by Rule 16a-1 under the Exchange Act).
4. Stock Available under the Plan
(a) Number of Shares . Subject to adjustment under Section 6, Options may be granted under the Plan for up to 3,500,000 shares of Common Stock. If any Option expires or is terminated, surrendered or canceled without having been fully exercised, the unused Common Stock covered by such Option shall again be available for the grant of Options under the Plan, subject, however, in the case of Incentive Stock Options (as hereinafter defined), to any limitation required under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.
(b) Per-Participant Limit . Subject to adjustment under Section 7, the maximum number of shares of Common Stock with respect to which an Option may be granted to any Participant under the Plan shall be 500,000 per calendar year. The per-Participant limit described in this Section 4(b) shall be construed and applied consistently with Section 162(m) of the Code.
5. Terms of Stock Options
(a) General . The Board may grant Options and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option which is not intended to be an Incentive Stock Option (as hereinafter defined) shall be designated a "Nonstatutory Stock Option".
Page 2
(b) Incentive Stock Options . An Option that the Board intends to be an "incentive stock option" as defined in Section 422 of the Code (an "Incentive Stock Option") shall only be granted to employees of the Company and shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) which is intended to be an Incentive Stock Option is not an Incentive Stock Option.
(c) Exercise Price . The Board shall establish the exercise price, which shall in no event be less than 100% of the fair market value of the Common Stock as determined (or in a manner approved) by the Board in good faith ("Fair Market Value") at the time of grant, at the time each Option is granted and specify it in the applicable option agreement.
(d) Duration of Options . Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement. No option will be granted for a term in excess of 10 years.
(e) Exercise of Option . Options may be exercised by delivery to the Company of a written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board, together with payment in full as specified in Section 5(f) for the number of shares for which the Option is exercised.
(f) Payment Upon Exercise. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:
(1) in cash or by check, payable to the order of the Company;
(2) except as the Board may, in its sole discretion, otherwise provide in an option agreement, (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price or (iii) delivery of shares of Common Stock owned by the Participant valued at their Fair Market Value, which Common Stock was owned by the Participant at least six months prior to such delivery;
(3) to the extent permitted by the Board, in its sole discretion (i) by delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (ii) by payment of such other lawful consideration as the Board may determine; or
(4) any combination of the above permitted forms of payment.
Page 3
6. Adjustments for Changes in Common Stock and Certain Other Events
(a) Changes in Capitalization . In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any distribution to holders of Common Stock other than a normal cash dividend, (i) the number and class of securities available under this Plan, (ii) the per-Participant limits set forth in Section 4(b), and (iii) the number and class of securities and exercise price per share subject to each outstanding Option shall be appropriately adjusted by the Company (or substituted Options may be granted, if applicable) to the extent the Board shall determine, in good faith, that such an adjustment (or substitution) is necessary and appropriate. If this Section 6(a) applies and Section 6(c) also applies to any event, Section 6(c) shall be applicable to such event, and this Section 6(a) shall not be applicable.
(b) Liquidation or Dissolution . In the event of a proposed liquidation or dissolution of the Company, the Board shall upon written notice to the Participants provide that all then unexercised Options will (i) become exercisable in full as of a specified time at least 10 business days prior to the effective date of such liquidation or dissolution and (ii) terminate effective upon such liquidation or dissolution, except to the extent exercised before such effective date.
(c) Acquisition Events
(1) Definition . An "Acquisition Event" shall mean: (a) any merger or consolidation of the Company with or into another entity as a result of which the Common Stock is converted into or exchanged for the right to receive cash, securities or other property or (b) any exchange of shares of the Company for cash, securities or other property pursuant to a statutory share exchange transaction.
(2) Consequences of an Acquisition Event on Options. Upon the occurrence of an Acquisition Event, or the execution by the Company of any agreement with respect to an Acquisition Event, the Board shall provide that all outstanding Options shall be assumed, or equivalent options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), provided that any options substituted for Incentive Stock Options shall satisfy, in the determination of the Board, the requirements of Section 424(a) of the Code. Notwithstanding the foregoing, if the acquiring or succeeding corporation (or an affiliate thereof) does not agree to assume, or substitute for, such Options, then the Board shall upon written notice to the Participants, provide that all then unexercised Options will become exercisable in full as of a specified time (the "Acceleration Time") prior to the Acquisition Event and will terminate immediately prior to the consummation of such Acquisition Event, except to the extent exercised by the Participants before the consummation of such Acquisition Event; provided, however, that, in the event of an Acquisition Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share of Common Stock surrendered pursuant to such Acquisition Event (the "Acquisition Price"), then the Board may instead provide that all outstanding Options shall terminate upon consummation of such Acquisition Event and that each Participant shall receive, in exchange therefor, a cash payment equal to the amount (if any) by which (A) the Acquisition Price multiplied by the number of shares of Common Stock subject to such outstanding Options (whether or not then exercisable), exceeds (B) the aggregate exercise price of such Options.
Page 4
(d) Acceleration of Options . Immediately prior to the consummation of a Change of Control, each then outstanding Option under the Plan shall become immediately exercisable as to twenty-five percent (25%) of the number of shares as to which such Option would otherwise not then be exercisable (rounded down to the nearest whole share), and the number of shares as to which each such Option shall become exercisable on each vesting date set forth in the applicable option agreement shall be reduced by 25%. In addition, all Options held by a Participant that are not terminated pursuant to Section 6(c) above shall immediately become exercisable in full if and when, within 24 months after a Change of Control, such Participant's employment with the Company (or the acquiring or succeeding entity) is involuntarily terminated by the Company (or such acquiring or succeeding entity) other than for Cause (as defined below).
(1) Definition of Change of Control . "Change of Control" shall mean:
(A) The acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of either (A) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (d)(1), the following acquisitions shall not constitute a Change of Control: (1) any acquisition directly from the Company, (2) any acquisition by the Company, (3) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (4) any acquisition by any corporation pursuant to a transaction which satisfies the criteria set forth in clauses (A), (B) and (C) of subsection (d)(1)(C) of this Section 6; or
(B) Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequently to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
Page 5
(C) Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Business Combination"), in each case, unless, immediately following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of, respectively, the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, of the corporation resulting from such Business Combination (which as used in this Section 6(d)(1)(C) shall include, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination, or the combined voting power of the then-outstanding voting securities of such corporation and (C) at least half of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
(D) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.
(2) Definition of Cause . "Cause" shall mean:
(A) the failure of the Participant to perform substantially the Participant's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness), which failure is not cured within 30 days after a written demand for substantial performance is delivered to the Participant by the Participant's manager or the Board which specifically identifies the manner in which such manager or the Board, as applicable, believes that the Participant has not substantially performed the Participant's duties, or
(B) the engaging by the Participant in illegal conduct or gross misconduct which is injurious to the Company."
Page 6
7. General Provisions Applicable to Options
(a) Transferability of Options . Except as the Board may otherwise determine or provide in an Option, Options shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.
(b) Documentation . Each Option shall be evidenced by a written instrument in such form as the Board shall determine. Each Option may contain terms and conditions in addition to those set forth in the Plan.
(c) Board Discretion . Except as otherwise provided by the Plan, each Option may be made alone or in addition or in relation to any other Option. The terms of each Option need not be identical, and the Board need not treat Participants uniformly.
(d) Termination of Status . The Board shall determine the effect on an Option of the disability, death, retirement, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, the Participant's legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Option.
(e) Withholding . Each Participant shall pay to the Company, or make provision satisfactory to the Board for payment of, any taxes required by law to be withheld in connection with Options to such Participant no later than the date of the event creating the tax liability. Except as the Board may otherwise provide in an Option, Participants may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Option creating the tax obligation, valued at their Fair Market Value. The Company may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to a Participant.
(f) Amendment of Option . The Board may amend, modify or terminate any outstanding Option, including but not limited to, substituting therefor another Option of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that the Participant's consent to such action shall be required unless the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant. In addition, neither the Board nor the Company may amend the terms of any issued and outstanding Options to reduce the exercise price, other than pursuant to Section 6 of the Plan, without the prior approval of the Company's stockholders.
Page 7
(g) Conditions on Delivery of Stock . The Company will not be obligated to deliver any shares of Common Stock upon exercise of any Option until (i) all conditions of the Option have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company's counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations.
(h) Acceleration . The Board may at any time provide that any Options shall become immediately exercisable in full or in part.
8. Miscellaneous
(a) No Right To Employment or Other Status . No person shall have any claim or right to be granted an Option, and the grant of an Option shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Option.
(b) No Rights As Stockholder . Subject to the provisions of the applicable Option, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be issued upon exercise of an Option until becoming the record holder of such shares. Notwithstanding the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to such Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date for such stock dividend and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.
(c) Effective Date and Term of Plan . The Plan shall become effective on the date on which it is approved by the Company's stockholders . No Options shall be granted under the Plan after the completion of ten years from the date the Plan was approved by the Board, but Options previously granted may extend beyond that date.
Page 8
(d) Amendment of Plan . The Board may amend, suspend or terminate the Plan or any portion thereof at any time, provided that, to the extent required by Section 162(m), no Option granted to a Participant designated as subject to Section 162(m) by the Board after the date of such amendment shall become exercisable, realizable or vested, as applicable to such Option (to the extent that such amendment to the Plan was required to grant such Option to a particular Participant), unless and until such amendment shall have been approved by the Company's stockholders as required by Section 162(m) (including the vote required under Seciton 162(m)). In addition, the second sentence of Section 7(f) of the Plan may not be amended by the Board without the prior approval of the Company's stockholders.
(e) Governing Law . The provisions of the Plan and all Options made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, without regard to any applicable conflicts of law.
Approved by the Board of Directors February 12, 1998.
Adopted by stockholders on May 15, 1998.
Amended by the Board of Directors on February 16, 1999.
Amendment approved by stockholders on May 19, 1999.
Amended by the Board of Directors on February 16, 2000.
Amendment approved by stockholders on May 17, 2000.
Amendment approved by the Board of Directors on May 23, 2001.
Amendment approved by the Board of Directors on February 13, 2002.
Page 9
EXHIBIT 10.11
IDEXX LABORATORIES, INC. |
AMENDED AND RESTATED AGREEMENT |
This Agreement, dated as of October 17, 2001, amends and restates in its entirety the Agreement dated as of August 26, 1999 between IDEXX Laboratories, Inc. ("IDEXX") and David E. Shaw ("Shaw") regarding Shaw's reappointment as Chief Executive Officer of IDEXX, and the planned recruitment and appointment of a person to succeed Shaw as such Chief Executive Officer. In consideration of Shaw's willingness to serve as Chief Executive Officer pending the identification and appointment of a successor (the "Succession"), and to serve as Executive Chairman for a period of time after the Succession, and for other good and valuable consideration, the parties agree as follows:
1. |
From the date hereof until the earlier of the date of the Succession or June 30, 2002 (the |
"CEO Term"), Shaw agrees to serve, and IDEXX agrees to retain Shaw, as Chief |
|
Executive Officer, unless Shaw resigns prior to expiration of the CEO Term. During the |
|
CEO Term, Shaw will perform responsibilities consistent with his position as Chief |
|
Executive Officer and will assist in the recruitment of a successor. |
|
2. |
If and as long as requested by the Board of Directors, for the period from the end of the |
CEO Term to up to two years thereafter (such period, the "Executive Chairman Term" |
|
and together with the CEO Term, the "Term"), Shaw agrees to serve as a part-time |
|
employee of IDEXX with the title of "Executive Chairman." During the Executive |
|
Chairman Term, Shaw will perform part-time responsibilities consistent with his |
|
position as Executive Chairman, as mutually agreed with the Board of Directors. It is |
|
expected that such responsibilities will be primarily in the areas of strategy and |
|
acquisitions. |
|
3. |
Shaw's annual base salary during the CEO Term shall initially be $500,000, and will be |
subject to change during the CEO Term by mutual agreement. Eligibility for cash |
|
bonuses or stock option grants will be at the discretion of IDEXX's Board of Directors |
|
but consistent with senior officer guidelines. In consideration for Shaw's extended |
|
service to the Company since its inception and his willingness to assist with the |
|
succession, during the two-year period following the end of the CEO Term, regardless |
|
whether Shaw is requested to serve as Executive Chairman, IDEXX shall pay to Shaw |
|
an annual sum of $500,000, payable in equal bi-weekly installments, provided that |
|
payments under this sentence shall cease if and when Shaw is entitled to any payment |
|
under the Employment Agreement dated April 25, 1997 between Shaw and IDEXX (the |
|
"Employment Agreement") as a result of a Change of Control (as defined therein). |
|
4. |
During both the CEO Term and Executive Chairman Term, Shaw will participate on the |
same basis and at the same level that he currently participates in IDEXX health |
|
insurance and other benefit programs, including the availability of on-site and off-site |
|
administrative support and office facilities. |
|
Page 1 | |
5. |
All of Shaw's options to purchase shares of IDEXX common stock shall become vested |
and exercisable in full upon the last day of the Term, unless he voluntarily resigns prior |
|
to the end of the Term. |
|
6. |
The Employment Agreement will remain in effect and, in the event of any conflict or |
inconsistency between this Agreement and such Employment Agreement, this |
|
Agreement shall control. For purposes of the Employment Agreement, from and after |
|
the end of the CEO Term: (a) the Employment Period shall be deemed to end upon |
|
expiration of the Executive Chairman Term, (b) the responsibilities of Shaw shall be as |
|
set forth in this Agreement rather than Section 4 of the Employment Agreement, and (c) |
|
Shaw's "Annual Base Salary" for purposes of Section 6(a)(i)(B) of the Employment |
|
Agreement shall mean Shaw's annual base salary as of the end of the CEO Term. |
|
Agreed to as of October 17, 2001. |
|
IDEXX Laboratories, Inc.: |
|
By: /s/ James, L. Moody, Jr._________ |
By: /s/ David E. Shaw__________ |
James L. Moody, Jr., Chairman |
David E. Shaw |
Compensation Committee |
Page 2
EXHIBIT 10.13
Agreement |
1. Title and Responsibilities
President, Chief Executive Officer and Chairman of the Board of Directors.
2. Cash Compensation
$500,000 annualized base salary, plus participation in annual senior management cash performance bonus programs with an expectation of a cash bonus of 100% of base compensation if personal and corporate goals are achieved. The board would be pleased to consider changes in incentive compensation programs for you and others at IDEXX in the future. Performance reviews with consideration of merit increases are performed by the Compensation Committee annually on a calendar year basis.
3. Stock Options
Hiring grant of an option to purchase 450,000 shares of IDEXX common stock subject to 20% annual vesting over five years, and exercisable over 10 years. This option will be granted by the IDEXX Board of Directors at the fair market value at the time of the grant and will be subject to the terms of the IDEXX Stock Option Agreement and the Company's incentive stock option plan. It has been customary in the past to make additional annual grants based on performance, and we would anticipate annual option grants for 80,000 to 120,000 shares depending on performance against goals as outlined by the Compensation Committee.
4. Executive Employment Agreement
You will be protected under an Executive Employment Agreement similar to those currently in place for the current President and other IDEXX officers providing certain benefits applicable following a change in control of the Company.
5. Severance Benefits
If your employment is terminated at any time by the Company other than for cause (as defined below), for a period of two years following such termination the Company will continue to pay your base salary and provide you with benefits equivalent to those received by you prior to termination, and your stock options will continue to vest in accordance with their terms over such period. For these purposes "cause" is defined as (a) willful, material misconduct, (b) gross negligence in the performance of your duties on behalf of the Company, or (c) a breach of either your invention and non-disclosure agreement or non-compete agreement with the Company.
Page 1
6. IDEXX Benefits Programs
You will be eligible to participate in our 401K plan, our Employee Purchase Plan, our medical plan, and our life insurance (twice annual salary) and disability insurance (70% of salary) plans as provided in those plans.
7. Relocation
We expect you to relocate to the Portland area mid-2002, and to work at our Westbrook headquarters in the meantime. Reimbursement for relocation expenses will be based on IDEXX relocation expense policies.
8. Other Terms
All IDEXX employees must enter into non-compete and invention and non-disclosure agreements prior to the commencement of employment.
This agreement is conditioned upon approval by the IDEXX Board of Directors.
For IDEXX Laboratories, Inc. |
ACCEPTED: |
/s/ William F. Pounds, Ph.D. |
/s/ Jonathan W. Ayers |
William F. Pounds, Ph.D. |
Jonathan W. Ayers |
Date: January 22, 2002 |
Page 2
EXHIBIT 10.14
EXECUTIVE EMPLOYMENT AGREEMENT |
THIS EMPLOYMENT AGREEMENT is made as of January 28, 2002, (this "Agreement"), by and between IDEXX Laboratories, Inc., a Delaware corporation (the "Company") and Jonathan W. Ayers (the "Executive").
The Board of Directors of the Company (the "Board") has determined that it is in the best interests of the Company and its shareholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the possibility, threat or occurrence of a Change of Control (as defined below) of the Company. The Board believes it is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by a pending or threatened Change of Control and to encourage the Executive's full attention and dedication to the Company currently and in the event of any threatened or pending Change of Control, and to provide the Executive with compensation and benefits arrangements upon a Change of Control which ensure that the compensation and benefits expectations of the Executive will be satisfied and which are competitive with those of other corporations. Therefore, in order to accomplish these objectives, the Board has caused the Company to enter into this Agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
1. Certain Definitions .
(a) The "Effective Date" shall mean the first date during the Change of Control Period (as defined in Section 1(b)) on which a Change of Control (as defined in Section 2) occurs. Anything in this Agreement to the contrary notwithstanding, if a Change of Control occurs and if the Executive's employment with the Company is terminated prior to the date on which the Change of Control occurs, and if it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change of Control or (ii) otherwise arose in connection with or anticipation of a Change of Control, then for all purposes of this Agreement the "Effective Date" shall mean the date immediately prior to the date of such termination of employment.
(b) The "Change of Control Period" shall mean the period commencing on the date hereof and ending on the third anniversary of the date hereof; provided, however, that commencing on the date one year after the date hereof, and on each annual anniversary of such date (such date and each annual anniversary thereof shall be hereinafter referred to as the "Renewal Date"), unless previously terminated, the Change of Control Period shall be automatically extended so as to terminate three years from such Renewal Date, unless at least 120 days prior to the Renewal Date the Company shall give notice to the Executive that the Change of Control Period shall not be so extended.
Page 1
2. Change of Control . For the purpose of this Agreement, a "Change of Control" shall mean:
(a) The acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (i) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iv) any acquisition by any corporation pursuant to a transaction which satisfies the criteria set forth in clauses (i), (ii) and (iii) of subsection (c) of this Section 2; or
(b) Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequently to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
(c) Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Business Combination"), in each case, unless, immediately following such Business Combination, (i) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of, respectively, the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, of the corporation resulting from such Business Combination (which as used in this Section 2(c) shall include, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination, or the combined voting power of the then-outstanding voting securities of such corporation and (iii) at least half of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
(d) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.
3. Employment Period . The Company hereby agrees to continue the Executive in its employ, and the Executive hereby agrees to remain in the employ of the Company subject to the terms and conditions of this Agreement, for the period commencing on the Effective Date and ending on the earlier of (i) the third anniversary of such date or (ii) the termination of the Executive's employment pursuant to Section 5 hereof (the "Employment Period"). Except as provided in Section 1(a), nothing in this Agreement shall, prior to the Effective Date, impose upon the Company any obligation to retain the Executive as an employee. In addition, nothing in this Agreement shall restrict the Executive from terminating his employment with the Company, and no such termination by the Executive shall be deemed a breach of this Agreement.
Page 2
4. Terms of Employment .
(a) Position and Duties .
(i) During the Employment Period, (A) the Executive's position (including status, offices, titles and reporting requirements), authority, duties and responsibilities shall be at least commensurate in all material respects with the most significant of those held, exercised and assigned at any time during the 120-day period immediately preceding the Effective Date and (B) the Executive's services shall be performed at the location where the Executive was employed immediately preceding the Effective Date or any office or location less than 35 miles from such location.
(ii) During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote reasonable attention and time during normal business hours to the business and affairs of the Company and, to the extent necessary to discharge the responsibilities assigned to the Executive hereunder, to use the Executive's reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period it shall not be a violation of this Agreement for the Executive to (A) serve on corporate, civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions, and (C) manage personal investments, so long as such activities do not significantly interfere with the performance of the Executive's responsibilities as an employee of the Company or the terms of this Agreement. It is expressly understood and agreed that to the extent that any such activities have been conducted by the Executive prior to the Effective Date, the continued conduct of such activities (or the conduct of activities similar in nature and scope thereto) subsequent to the Effective Date shall not thereafter be deemed to interfere with the performance of the Executive's responsibilities to the Company.
Page 3
(b) Compensation .
(i) Base Salary . During the Employment Period, the Executive shall receive an annual base salary ("Annual Base Salary"), which shall be paid at a monthly rate, at least equal to twelve times the highest monthly base salary paid or payable, including any base salary which has been earned but deferred, to the Executive by the Company and its affiliated companies in respect of the twelve-month period immediately preceding the month in which the Effective Date occurs. During the Employment Period, the Annual Base Salary shall be reviewed no more than 12 months after the last salary increase awarded to the Executive prior to the Effective Date and thereafter at least annually. Any increase in Annual Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement. Annual Base Salary shall not be reduced after any such increase and the term Annual Base Salary as utilized in this Agreement shall refer to Annual Base Salary as so increased. As used in this Agreement, the term "affiliated companies" shall include any company controlled by, controlling or under common control with the Company.
(ii) Annual Bonus . In addition to Annual Base Salary, the Executive shall be entitled to receive such annual bonus as may be determined by the Board of Directors, but in no event less than the annual bonus paid or payable in respect of the full fiscal year immediately preceding the Effective Date.
(iii) Incentive Plans . During the Employment Period, the Executive shall be entitled to participate in all incentive plans, practices, policies and programs applicable generally to other peer executives of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with benefits which are less favorable, in the aggregate, than the most favorable of such plans, practices, policies and programs in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its affiliated companies.
(iv) Welfare Benefit, Savings and Retirement Plans . During the Employment Period, the Executive and/or the Executive's family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit, savings and retirement plans, practices, policies and programs provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life, split-dollar life, accidental death and travel accident insurance plans and programs) to the extent applicable generally to other peer executives of the Company, but in no event shall such plans, practices, policies and programs provide the Executive with benefits which are less favorable, in the aggregate, than the most favorable of such plans, practices, policies and programs in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its affiliated companies.
(v) Expenses . During the Employment Period, the Executive shall be entitled to receive reimbursement for all reasonable expenses incurred by the Executive in accordance with the policies, practices and procedures of the Company in effect immediately prior to the Effective Date.
(vi) Vacation . During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with benefits which are less favorable, in the aggregate, than the most favorable of such plans, practices, policies and programs in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its affiliated companies.
(c) Options . Upon the occurrence of a Change of Control, all outstanding options to purchase shares of Common Stock held by the Executive shall become immediately exercisable in full.
Page 4
5. Termination of Employment .
(a) Death or Disability . The Executive's employment shall terminate automatically upon the Executive's death during the Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the Employment Period (pursuant to the definition of Disability set forth below), it may give to the Executive written notice in accordance with Section 12(b) of this Agreement of its intention to terminate the Executive's employment. In such event, the Executive's employment with the Company shall terminate effective on the 30 th day after receipt of such notice by the Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, the Executive shall not have returned to full-time performance of the Executive's duties. For purposes of this Agreement, "Disability" shall mean the absence of the Executive from the Executive's duties with the Company on a full-time basis for 180 consecutive business days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive's legal representative.
(b) Cause . Subject to Section 5(d), the Company may terminate the Executive's employment during the Employment Period for Cause. For purposes of this Agreement, "Cause" shall mean:
(i) the willful failure of the Executive to perform substantially the Executive's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness), which failure is not cured within 30 days after a written demand for substantial performance is delivered to the Executive by the Board which specifically identifies the manner in which the Board believes that the Executive has not substantially performed the Executive's duties, or
(ii) the willful engaging by the Executive in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.
Page 5
For purposes of this provision, no act or failure to act, on the part of the Executive, shall be considered "willful" unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive's action or omission was in the best interests of the Company.
(c) Good Reason . The Executive's employment may be terminated by the Executive with or without Good Reason. For purposes of this Agreement, "Good Reason" shall mean:
(i) the assignment to the Executive of any duties inconsistent in any respect with the Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as contemplated by Section 4(a) of this Agreement, or any other action by the Company which results in a diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Executive;
(ii) any failure by the Company to comply with any of the provisions of Section 4(b) of this Agreement or any other provision hereof requiring a payment or provision of a benefit to the Executive, other than an isolated, insubstantial and inadvertent failure not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Executive;
(iii) the Company's requiring the Executive to be based at any office or location other than as provided in Section 4(a)(i)(B) hereof or the Company's requiring the Executive to travel on Company business to a substantially greater extent than required immediately prior to the Effective Date;
(iv) any purported termination by the Company of the Executive's employment otherwise than as expressly permitted by this Agreement; or
(v) any failure by the Company to comply with and satisfy Section 11(c) of this Agreement.
For purposes of this Section 5(c), any good faith determination of "Good Reason" made by the Executive shall be conclusive.
Anything in this Agreement to the contrary notwithstanding, a termination by the Executive for any reason during the 30-day period immediately following the first twelve (12) months after the Effective Date shall be deemed to be a termination for Good Reason for all purposes of this Agreement.
Page 6
(d) Notice of Termination .
(i) Any termination by the Company for Cause, or by the Executive for Good Reason, shall be effected by Notice of Termination to the other party hereto given in accordance with Section 12(b) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than thirty days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstances in enforcing the Executive's or the Company's rights hereunder.
(ii) Any Notice of Termination for Cause must be given within sixty (60) days of the Board learning of the event(s) or circumstance(s) which the Board believes constitute(s) Cause. Prior to any Notice of Termination for Cause being given (and prior to any termination for Cause being effective), the Executive shall be entitled to a hearing before the Board at which he may, at his election, be represented by counsel and at which he shall have a reasonable opportunity to be heard. Such hearing shall be held on not less than fifteen days prior written notice to the Executive stating the Board's intention to terminate the Executive for Cause and stating in detail the particular event(s) or circumstance(s) which the Board believes constitute(s) Cause for termination.
(e) Date of Termination . "Date of Termination" means (i) if the Executive's employment is terminated by the Company for Cause, or by the Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, subject, in the case of termination by the Company, for Cause, to the Company's compliance with Section 5(d)(ii); (ii) if the Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date on which the Company notifies the Executive of such termination; and (iii) if the Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of the Executive or the Disability Effective Date, as the case may be.
6. Obligations of the Company Upon Termination .
(a) Good Reason; Other Than for Cause, Death or Disability . If, during the Employment Period, the Company shall terminate the Executive's employment other than for Cause, Death or Disability or the Executive shall terminate employment for Good Reason:
(i) the Company shall pay to the Executive in a lump sum in cash within 30 days after the Date of Termination the aggregate of the following amounts:
A. the sum of (1) the Executive's Annual Base Salary through the Date of Termination to the extent not theretofore paid, (2) the product of (x) the higher of (I) the highest annual cash bonus paid to the Executive with respect to the last three fiscal years prior to the Effective Date and (II) the annual bonus paid or payable, including any bonus or portion thereof which has been earned but deferred (and annualized for any fiscal year consisting of less than twelve full months or during which the Executive was employed for less than twelve full months), for the most recently completed fiscal year during the Employment Period, if any (such higher amount being referred to as the "Highest Annual Bonus") and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365 and (3) any compensation previously deferred by the Executive (together with any accrued interest or earnings thereon) and any accrued vacation pay, in each case to the extent not theretofore paid (the sum of the amounts described in clauses (1), (2), and (3) shall be hereinafter referred to as the "Accrued Obligations"); and
Page 7
B. the amount equal to the product of (1) three and (2) the sum of (x) the Executive's Annual Base Salary and (y) the Highest Annual Bonus.
(ii) for 36 months after the Executive's Date of Termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue benefits to the Executive and/or the Executive's family at least equal to those which would have been provided to them in accordance with the plans, programs, practices and policies described in Section 4(b)(iv) of this Agreement (excluding any savings and/or retirement plans) if the Executive's employment had not been terminated or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies and their families, provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits described herein shall be secondary to those provided under such other plan during such applicable period of eligibility. For purposes of determining eligibility (but not the time of commencement of benefits) of the Executive for retiree benefits pursuant to such plans, practices, programs and policies, the Executive shall be considered to have remained employed until 36 months after the Date of Termination and to have retired on the last day of such period;
(iii) to the extent not theretofore paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"); and
(iv) the Company shall timely reimburse the Executive up to an aggregate of $25,000 for expenses incurred in connection with outplacement services and relocation costs incurred in connection with obtaining new employment outside the State of Maine until the earlier of (i) 36 months following the termination of Executive's employment or (ii) the date the Executive secures full time employment.
(b) Death . If the Executive's employment is terminated by reason of the Executive's death during the Employment Period, this Agreement shall terminate without further obligations to the Executive's legal representatives under this Agreement, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to the Executive's estate or beneficiary, as applicable, in a lump sum in cash within 30 days of the Date of Termination.
(c) Disability . If the Executive's employment is terminated by reason of the Executive's Disability during the Employment Period, this Agreement shall terminate without further obligations to the Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination.
(d) Cause; Other than for Good Reason . If the Executive's employment shall be terminated for Cause during the Employment Period, this Agreement shall terminate without further obligations to the Executive other than the obligation to pay to the Executive (x) his Annual Base Salary through the Date of Termination, (y) the amount of any compensation previously deferred by the Executive, and (z) Other Benefits, in each case to the extent theretofore unpaid or not yet provided. If the Executive voluntarily terminates employment during the Employment Period, excluding a termination for Good Reason, this Agreement shall terminate without further obligations to the Executive, other than for Accrued Obligations and the timely payment or provision of Other Benefits. In such case, all Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination.
Page 8
7. Nonexclusivity of Rights . Nothing in this Agreement shall prevent or limit the Executive's continuing or future participation in any plan, program, policy or practice provided by the Company or any of its affiliated companies and for which the Executive may qualify, nor, subject to Section 12(f), shall anything herein limit or otherwise affect such rights as the Executive may have under any contract or agreement with the Company or any of its affiliated companies. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.
8. Full Settlement . The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive (under this Agreement or otherwise) or others. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not the Executive obtains other employment. The Company agrees to pay as incurred, to the full extent permitted by law, all legal, accounting and other fees and expenses (including, without limitation, of expert witnesses) which the Executive may reasonably incur (i) as a result of any contest (regardless of the outcome thereof) by the Company, the Executive or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive about the amount of any payment pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Internal Revenue Code of 1986, as amended (the "Code"), (ii) in connection with the negotiation and preparation of this Agreement and (iii) in connection with the Executive's performance of his obligations under Section 9(c).
9. Certain Additional Payments by the Company .
(a) Anything in this Agreement to the contrary notwithstanding and except as set forth below, in the event it shall be determined that any payment, benefit, or distribution by the Company to or for the benefit of the Executive which constitutes a "parachute payment" within the meaning of Section 280G of the Code (whether provided pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section 9)(a "Payment") would be subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties are incurred by the Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the "Excise Tax"), then the Executive shall be entitled to receive an additional payment (a "Gross-Up Payment") in an amount such that after payment by the Executive of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and excise tax imposed upon the Gross-Up Payment, the Executive retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Notwithstanding the foregoing provisions of this Section 9(a), if it shall be determined that the Executive is entitled to a Gross-Up Payment, but that the Executive, after taking into account the Payments and the Gross-Up Payment, would not receive a net after-tax benefit of at least $50,000 (taking into account both income taxes and any Excise Tax) as compared to the net after-tax proceeds to the Executive resulting from an elimination of the Gross-Up Payment and a reduction of the Payments, in the aggregate, to an amount (the "Reduced Amount") such that the receipt of Payments would not give rise to any Excise Tax, then no Gross-Up Payment shall be made to the Executive and the Payments, in the aggregate, shall be reduced to the Reduced Amount.
(b) Subject to the provisions of Section 9(c), all determinations required to be made under this Section 9, including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by Arthur Andersen LLP or such other certified public accounting firm as may be designated by the Executive (the "Accounting Firm") which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the receipt of notice from the Executive that there has been a Payment, or such earlier time as is requested by the Company. In the event that the Accounting Firm is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Executive shall appoint another nationally recognized accounting firm to make the determinations required hereunder (which accounting firm shall then be referred to as the Accounting Firm hereunder). All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any Gross-Up Payment, as determined pursuant to this Section 9, shall be paid by the Company to the Executive within five days of the receipt of the Accounting Firm's determination. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that Gross-Up Payments which will not have been made by the Company should have been made ("Underpayment"), consistent with the calculations required to be made hereunder. In the event that the Company exhausts its remedies pursuant to Section 9(c) and the Executive thereafter is required to make a payment of any Excise Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive.
Page 9
(c) nbsp; The Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of the Gross-Up Payment. Such notification shall be given as soon as practicable but no later than ten business days after the Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such claim is requested to be paid. The Executive shall not pay such claim prior to the expiration of the 30-day period following the date on which it gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies the Executive in writing prior to the expiration of such period that it desires to contest such claim, the Executive shall:
give the Company any information reasonably requested by the Company and available to the Executive relating to such claim,
(i) take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,
(ii) cooperate with the Company in good faith in order effectively to contest such claim, and
(iii) permit the Company to participate in any proceedings relating to such claim;
Page 10
provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold the Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limitation on the foregoing provisions of this Section 9(c), the Company shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct the Executive to pay the tax claimed and sue for a refund or to contest the claim in any permissible manner, and the Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the Company directs the Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to the Executive, on an interest-free basis and shall indemnify and hold the Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of the Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and the Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or other taxing authority.
(d) If, after the receipt by the Executive of an amount advanced by the Company pursuant to Section 9(c), the Executive becomes entitled to receive any refund with respect to such claim, the Executive shall (subject to the Company's complying with the requirements of Section 9(c)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes applicable thereto). If, after the receipt by the Executive of an amount advanced by the Company pursuant to Section 9(c), a determination is made that the Executive shall not be entitled to any refund with respect to such claim and the Company does not notify the Executive in writing of its intent to contest such denial of refund prior to the expiration of 30 days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid.
10. Confidential Information . The Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data relating to the Company or any of its affiliated companies, and their respective businesses, which shall have been obtained by the Executive during the Executive's employment by the Company or any of its affiliated companies and which shall not be or become public knowledge (other than by acts by the Executive or representatives of the Executive in violation of this Agreement). After termination of the Executive's employment with the Company, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those designated by it. In no event shall an asserted violation of the provisions of this Section 10 constitute a basis for deferring or withholding any amounts or benefits otherwise payable or to be provided to the Executive under this Agreement.
Page 11
11. Successors .
(a) This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive's legal representatives.
(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
(c) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid.
12. Miscellaneous .
(a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.
(b) All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
Page 12
If to the Executive: |
|
Jonathan W. Ayers |
|
c/o IDEXX Laboratories, Inc. |
|
One IDEXX Drive |
|
Westbrook, ME 04092 |
|
If to the Company: |
|
IDEXX Laboratories, Inc. |
|
One IDEXX Drive |
|
Westbrook, ME 04092 |
|
Attention: Chairman of Compensation Committee |
|
or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.
(c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
(d) The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.
(e) The Executive's or the Company's failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation the right of the Executive to terminate employment for Good Reason pursuant to Section 5(c) of this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.
(f) The Executive and the Company acknowledge that, except as may otherwise be provided under any other written agreement between the Executive and the Company, the employment of the Executive by the Company is "at will" and, subject to Section 1(a) hereof, prior to the Effective Date, the Executive's employment and/or this Agreement may be terminated by either the Executive or the Company, by written notice to the other, at any time prior to the Effective Date, in which case the Executive shall have no further rights or obligations under this Agreement. From and after the Effective Date this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof.
(g) Any dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration, conducted before a panel of three arbitrators in Portland, Maine, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court of competent jurisdiction.
[Remainder of Page Intentionally Left Blank]
Page 13
IN WITNESS WHEREOF, the Executive has hereunto set the Executive's hand and, pursuant to the authorization from its Board of Directors, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.
EXECUTIVE: |
|
/s/ Jonathan W. Ayers ______________ |
|
Jonathan W. Ayers |
|
COMPANY: |
|
IDEXX Laboratories, Inc. |
|
By: /s/ James L. Moody, Jr. __________ |
|
Name: James L. Moody, Jr. |
|
Title: Director |
|
EXHIBIT 21
SUBSIDIARIES OF THE COMPANY
____________________NAME___________________ |
_JURISDICTION OF INCORPORATION_ |
Blue Ridge Pharmaceuticals, Inc. |
Delaware |
Cardiopet Incorporated |
Delaware |
Genera Technologies Limited |
England and Wales |
IDEXX Distribution Corporation |
Delaware |
IDEXX Europe B.V. |
The Netherlands |
IDEXX Food Safety Net Services, Inc. |
Delaware |
IDEXX GmbH |
Germany |
IDEXX Laboratories B.V. |
The Netherlands |
IDEXX Laboratories Canada Corporation |
Canada |
IDEXX Laboratories Foreign Sales Corporation |
U.S. Virgin Islands |
IDEXX Laboratories Italia S.r.l. |
Italy |
IDEXX Laboratories, KK |
Japan |
IDEXX Laboratories Limited |
England and Wales |
IDEXX Laboratories (NZ) Limited |
New Zealand |
IDEXX Laboratories Pty. Limited |
Australia |
IDEXX Laboratories, S. de R.L. de C.V. |
Mexico |
IDEXX Laboratorios, S.L. |
Spain |
IDEXX Laboratories (Taiwan) Inc. |
Taiwan R.O.C. |
IDEXX Management Services Europe S.A. |
France |
IDEXX S.A.R.L. |
France |
IDEXX Scandinavia AB |
Sweden |
IDEXX Service, S.A. de C.V. |
Mexico |
IDEXX UK Acquisition Limited |
England and Wales |
IDEXX Veterinary Services, Inc. |
Delaware |
TD Acquisition Corp. |
Delaware |
VetConnect Systems, Inc. |
Delaware |
Veterinary Pathology Services Pty. Limited |
Australia |
All of the Company's subsidiaries are wholly-owned.
Exhibit 23.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation of our report, included in this Form 10-K, into the Company's previously filed Registration Statement File Nos. 33-41806, 33-42845, 33-42846, 33-48404, 33-61494, 33-64202, 33-64204, 33-95616, 333-11201, 333-11199, 333-36009, 333-36007, 333-56685, 333-78765, 333-78769, 333-43172, 333-43170, 333-27733 and 333-70846.
/s/ Arthur Andersen LLP
Boston, Massachusetts
March 18, 2002
Exhibit 99
IDEXX LABORATORIES, INC. |
||
One IDEXX Drive |
||
Westbrook, ME 04092 |
||
March 21, 2002 |
||
Securities and Exchange Commission |
||
450 Fifth Street, N.W. |
||
Judiciary Plaza |
||
Washington, DC 20549 |
||
Re: |
Confirmation of Arthur Andersen Representations |
Ladies and Gentlemen:
This letter confirms that IDEXX Laboratories, Inc. has received from Arthur Andersen LLP, the independent public accountant engaged by the company to examine the company's financial statements that are included in the Form 10-K to which this letter is filed as an exhibit, a representation letter addressed to the company and stating that: the audit conducted by Andersen was subject to Andersen's quality control system for the U.S. accounting and auditing practice to provide reasonable assurance that the engagement was conducted in compliance with professional standards; and there was appropriate continuity of Andersen personnel working on the audit, availability of national office consultation and availability of personnel at foreign affiliates of Andersen to conduct the relevant portions of the audit.
Very truly yours, |
|
IDEXX LABORATORIES, INC. |
|
By: /s/ Merilee Raines |
|
Name: Merilee Raines |
|
Title: Vice President, Finance and Treasurer |